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This project was undertaken to increase the understanding of platelet function, with 
paticular emphasis on abnormal platelets in diabetes mellitus, and improving the quality of 
platelet concentrates for transfusion. 
(1 } Potential platelet antagonists, including PGE1, verapamil, insulin and hirudin, 
were added to platelet concentrates in an attempt to improve the recovery and shelf-life of the 
concentrate. Each "preservative" caused some improvement in platelet concentrate quality, as 
measured by functional tests, and radio-immunoassay for the platelet activation marker, B- 
thromboglobulin. The best results were obtained with the addition of PGE1, which facilitated 
recovery of all samples to which it was added, suggesting a cheap way of ensuring 
consistently good platelet concentrates. 
(2) Various investigations were carried out regarding abnormal platelet function in 
diabetes mellitus. No significant differences were found in the responses of platelets from 
diabetics and age-matched controls to the calcium-channel blocking drug, Verapamil, in 
vitro. Similarly, the capacity of diabetic platelets to produce malondialdehyde, a by-product 
of thromboxane A2 synthesis, was not significantly different from control platelets. 
The use of insulin in aggregometry studies showed, surprisingly, that insulin could 
have a pro-aggregatory effect on platelets from diabetics, but not those from healthy controls. 
In addition, evidence for the existence of a platelet aggregation-enhancing factor in the 
plasma of diabetics and older controls was obtained. 
(3) Extensive tests to investigate the nature of spontaneous platelet aggregation (SPA) in 
whole blood have established the existence of two types of SPA, (i) ADP-dependent, and (ii) 
ADP-independent. The results obtained suggest a major role for erythrocytes in the 
development of inappropriate platelet aggregation. 
Chapter I1 
INTRODUCTION 
Platelets were first identified in human blood smears by four independent researchers 
in 1842. Various explanations as to their origins and function were put forward. Zimmerman 
in 1846 reported that he believed the "elementarblaschen" were red cell precursors 
1. Shultze, 
20 years later put forward the idea that the particles were fragmentation products of white 
cells that were able to come together to form a granular mass 1. 
By the 1870's it was clear that the particles were a distinct shaped element of the 
blood, but the hypothesis that they were red cell precursors persisted and they were termed 
"hematoblasts" by Hayem 1. During the later years of the century it was established that the 
particles were formed in the bone marrow by giant cells named "megakaryocytes" and that 
the fragments released by these cells were important in coagulation and clot retraction. Hence 
they were renamed "thrombocytes" by Deckhuzyen in 19011. 
The ability of platelets to form aggregates and release vasoconstrictor substances was 
soon established, but the fundamental role of platelets only really came to be understood in 
the 1950's when the release mechanism of platelets was identified 
1 , 2. Since then much has 
been learned about the physiological and biochemical details of platelet function and about 
what can go wrong if platelets fail to do their job properly. 
1.2 Platelets: Morphology. 
Platelets are not true cells, rather they are anucleated fragments of the giant bone- 
marrow cells, megakryocytes. When fully mature, megkaryocytes break up to form several 
thousand platelets which are released into the circulation. The platelet is a roughly discoid 
object, with an average volume of 5 to 7.5 fl (figure 1.1). 
The lack of a nucleus means that platelets have no DNA and very little ability to 
synthesise proteins. Hence, once released into the blood they age slowly and die within about 
2 
10 days3. Human blood typically contains 2-4 x 108 platelets / ml, but this can vary greatly 
in certain disease states3. 
The discoid shape of the platelet is maintained by a ring of microtubules which form a 
framework around the inner perimeter of the platelet. This framework, or cytoskeleton, 
consists of actino-myosin filaments similar to those seen in muscle fibres. These contractile 
proteins give the platelet its elasticity, and are essential in platelet shape change, release 
reaction and clot retraction4 (see section 1.4). 
The platelet plasma membrane is covered by a 15 - 20 nm thick coat, the 
glycocalyx3'4 that is rich in glycopoteins and glycolipids. The two most prominent 
glycoproteins are termed GP-11b and GP-IIIa, with approximately 50,000 copies of each per 
platelet4. GP-IIb is a dimer with subunits of mass 132 kD and 23 kD, and GP-111a is a single 
polypeptide of mass 95 kD with approximately 27 disulphide bonds5. Platelet stimulation 
leads to conformational changes resulting in the formation of GP-IIb/GP-IIIa complexes, 
which are thought to serve as receptors for fibrinogen, von Willebrand's factor and 
fibronectin. The second most prominent glycoprotein is GP-Ib with about 25,000 copies per 
platelet. It consists of two disulphide-linked subunits of mass 143 kD and 22 kD and is a 
potential receptor for von Willebrand's factor and thrombin4. GP-Ib is thought to be 
important in clot retraction since it becomes linked to the platelet cytoskeleton via actin- 
binding-protein on platelet activation4 (see section 1.4). The other major platelet 
glycoproteins are GP-IIa, a protein of approximately 138 kD which becomes expressed on 
stimulation of the platelet by thrombin, increasing from 800 sites to 9600 sites per platelet4, 
and GP-V, a 82 kD single-chain polypeptide that is the only known thrombin-substrate in the 
platelet plasma membrane. Treatment of platelets with thrombin results in the release of a 
69.5 kD hydrolytic fragment of this glycoprotein4. The functions of GP-11a and GP-V have 
yet to be ascertained. 
The plasma membrane itself has a typical trilaminar appearance but unlike the 
membranes of other blood cells it is invaginated at numerous points to form the surface- 
connected-canalicular system, a series of channels throughout the platelet cytoplasm that 
serve as outlets for platelet secretion3,4 
3 
Close associations have been described between the surface-connected-canalicular 
system and the dense tubular system. The dense tubular system originates from the 
endoplasmic reticulum of the parent megakaryocyte and consists of narrow, membrane- 
limited tubules, 40-60 nm in diameter4. This system contains enzyme activities such as 
peroxidase and glucose-6-phosphatase4. It also possesses Cat+-stimulated ATPase and 
adenylate cyclase activities and is thought to be involved in the regulation of intracellular 
Ca2+ transport. 
A variety of formed organelles and particulate elements are embedded in the 
cytoplasmic matrix of the platelet. In addition to common organelles such as mitochondria, 
lysosomes, microperoxisomes and glycogen stores, platelets possess specialised storage 
organelles known as alpha-granules and dense-bodies. Platelet mitochondria are simple in 
structure and few in number3. In addition to their normal metabolic functions, platelet 
mitochondria function as calcium stores similar to smooth-muscle mitochondria, releasing 
Ca2+ into the cytoplasm on platelet activation4. Lysosomes are small vesicles of 175-250 nm 
diameter that contain various enzymes that break up proteins and complex polysaccharides4. 
Lysosomal enzymes are released into the cytoplasm during platelet secretion, but their 
function is unclear. Microperoxisomes originate in megakaryocytes and contain the enzyme 
catalase which degrades toxic hydrogen peroxide. They are relatively few in number in 
platelets4. The glycogen stores take the form of granules, consisting of a collection of large 
molecules of the polymer with the enzymes responsible for its degradation to glucose bound 
to the surface of the granule2,3,4 
Of the platelet-specific organelles, by far the most numerous are the alpha-granules, 
forming the major proportion of platelet organelles. They are spherical or oval, 300-500 nm 
in diameter and contain a mixture of proteins including fibrinogen, platelet factor 4 (PF4), 
beta-thromboglobulin ((3-TG), fibronectin, albumin, platelet-derived-growth-factor (PDGF) 
and possibly GP-IIb and GP-I11a2'4. Fibrinogen and fibronectin are important platelet 
adhesive proteins, PF4 counteracts the anticoagulant effects of heparin4, and PDGF is a 
potent cell-growth stimulant4 The function of ß-TG is uncertain, but it may act as a granule 
packing protein4. 
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The second type of platelet granule is the dense body. They number up to about 15 
granules per platelet, with a mean of 5.4 per platelet, and are 200-300 nm in diameter. The 
dense bodies contain a highly concentrated mixture of the amine serotonin, calcium, ADP 
and ATP2,4. Dense bodies are not present in megakaryocytes, but precursor vesicles exist 
there which mature into dense bodies. Serotonin is taken up from the plasma by the 
platelets4. Dense bodies are the primary secretory organelles of the platelet and on platelet 
activation, release their contents into the plasma. 
Blood platelets are essential for normal haemostasis. They play two distinct roles in 
the cessation of haemorrhage, the haemostatic function and the thromboplastic function. The 
former is accomplished by the physical blocking of openings in blood vessels by masses of 
platelets known as thrombi, and the thromboplastic function involves the participation of 
chemical constituents of platelets in blood coagulation. 
Intact blood vessels have a continuous thin lining of endothelial cells that prevent the 
platelets coming into contact with the blood-vessel wall itself7. When a blood vessel is cut, 
the endothelial lining is disturbed and the fibrous matrix of the vessel wall is exposed. A 
major constituent of the matrix is collagen which serves as the primary stimulus for platelet 
activation, described in detail in the following section. Platelets in the blood flowing through 
the wound adhere to the collagen, setting in motion a complex cascade of platelet aggregation 
events and within a minute a haemostatic plug builds up, preventing any further blood loss. 
The occurrence of platelet activation can, under different circumstances, lead to 
serious pathological consequences. Abnormal or inappropriate platelet aggregation can lead 
to the formation of circulating thrombi or microaggregates potentially capable of occluding 
circulation and initiating a heart attack or stroke. 
5 
1.4. Platelets: Biochemistry of activation. 
There are several stimuli for platelet activation. One is the exposure of collagen fibres 
at sites of vascular injury, another is the release of pro-aggregatory agents from disrupted 
endothelial cells. Platelet agonists, together with their source are listed in table 1.1. 
The in vivo agonists listed are very different chemically, each has its own paticular 
receptor. The links between receptor and effector mechanisms are similar but not identical. 
Collagen is the most abundant protein in mammals, constituting a quarter of the total. 
It is present in nearly all organs and serves a major structural role. At least eight types of 
collagen have been identified in humans, differing in the nature of the triple-helical 
tropocollagen molecules that make up the collagen fibres6. Six different collagens are known 
to be present in blood vessels, namely types I, III, IV, V, VI and VIII7. Following injury to 
the blood vessel wall, collagen, present in the sub-endothelial matrix, is exposed and brought 
into contact with circulating blood. Platelets begin to adhere to the collagen, principally types 
I and III, the two most common types in blood vessels8. This is the first step in the cessation 
of bleeding. It has been suggested that platelets possess separate col lagen receptors, one 
mediating adhesion, and a second mediating aggregation. Saito et a! 
9 have tentatively 
identified a surface-bound, zymogen form of platelet factor XIII as the platelet's collagen- 
aggregation receptor. The initial adhesion receptor may be platelet GP-lb, or the GP-IIb/GP- 
IIIa complex, both of which are able to bind von Willebrand's factor, which in turn forms the 
adhesive 'glue' between the platelet and collagen. 
Platelet-collagen interactions set into motion a series of complex and poorly 
understood events within the platelet that result in the change of shape of the platelet from 
discoid to a 'spiny sphere' and the secretion of platelet granule contents. Amongst the granule 
contents released are further platelet agonists, including ADP, serotonin and PAF. 
Historically, ADP is the oldest of the agonists, having been recognised as a platelet activator 
since the initial observations of Hellem in 196011. ADP plays two roles that together produce 
platelet activation' 0. At low concentrations, (0.1 - 0.5µM) ADP causes shape change, 
followed by a reversible aggregation. At higher concentrations, irreversible, secondary 
aggregation with concomitant granule 
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ADP Nucleotide (i) Platelet dense Weak 
granules 
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(iii) Disrupted 
Endothelial cells 
Thrombin Proteolytic Plasma Prothrombin Strong 
enzyme 
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AGENT NATURE SOURCE MECHANISM 
Prostacylin Prostanoid Vascular Adenylate cyclase 
endothelium activation 
Antithrombin Polypeptide Liver Complexes thrombin 
III 
Ecto- Vascular ADP --------> ATP 
nucleotidases endothelium 
Table 1.2. In vivo Platelet aggregation inhibitors. 
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release is observed (see figure 1.2). The mechanism by which ADP causes platelet activation 
is by an inhibition of adenylate cyclase4. This causes a decrease in cytosolic cAMP, leading 
to increases in cytosolic Ca2+. This mechanism is discussed in detail later. However, recent 
work has suggested that platelets possess two ADP receptors, one linked to adenylate cyclase, 
and a second that is more directly linked to shape change and aggregation 10. The 'shape 
change' receptor has been identified as a single, I OOkD polypeptide, termed aggregin 
10 
Aggregin bears certain simlarities to GP-111a, a component of the fibrinogen receptor, but the 
two are not identical. The mode of action of aggregin is hypothesised to be as an inhibitor of 
the association between GP-IIb and GP-IIIa. On binding ADP, aggregin undergoes a 
conformational change that allows the two components of the fibrinogen receptor to associate 
and bind fibrinogen10. The shape change phenomenon may be mediated via a direct link 
between aggregin and/or the fibrinogen receptor and actinomyosin in the platelet 
cytoskeleton10 (see figure 1.3). 
The initial stages of activation of platelets by thrombin may also proceed via aggregin 
(figure 1.3). Thrombin is a 33.7kD active serine protease, synthesised as a 66kD zymogen 
called prothrombin6. Cleavage of prothrombin by activated coagulation factor X during the 
cogulation cascade leads to the generation of thrombin3. Thrombin appears to activate 
platelets by multiple mechanisms 
10,12 At very low concentrations (<1 nM) its action may 
depend on secretion of secondary agonists such as ADP, but unlike collagen, TxA2 and 
epinephrine, thrombin is also able to stimulate platelets by an ADP-independant 
mechanism 10. Two types of thrombin receptor have been identfied in human platelets 
10, the 
first (RI) is mediated by low concentrations of thrombin and is coupled to the inhibition of 
adenylate cyclase and actvation of phospholipase A2. R1 receptors are few in number 
(50/platelet), of high affinity (Kd=0.3nM) and probably represent the receptor for ADP- 
dependent actions. The second receptor type (R2) are intermedste in number (1700/platelet), 
with a moderate affinity (Kd=1 lnM) and require higher thrombin concentrations (>2nM). 
This receptor is linked to phospholipase C and hence to protein phosphorylation and IP3- 
dependent Ca2+ mobilisation 
10. The mechanisms for these activations are described later. 
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In addition to the thrombin receptors, platelets also possess thrombin substrates on 
their surface. The first substrate identified was GP-V, a single chain, 82kD polypeptide4. 
However, no evidence has been found to suggest that thrombin-induced cleavage of GP-V 
activates platelets. A more likely candidate is aggregin. Thrombin is believed to cleave 
aggregin by an indirect mechanism. On binding to GP-lb, thrombin causes activation of 
protein kinase C which in turn activates the intracellular protease, calpain. Calpain then 
cleaves aggregin, leaving the GP-IIb and GP-111a free to form their complex 10 
Thromboxane A2 (TxA2) is a product of the platelet's cyclooxygenase pathway (see 
figure 1.4). Stimulation of phospholipase C or phospholipase A2 by primary agonists leads to 
the liberation of arachidonic acid from membrane phospholipids, which is then converted to 
TxA2. TxA2 is then released into the plasma, where it acts as an autocoid, activating other 
platelets. The mechanism of TxA2 stimulation of platelets is considered to be via the 
lowering of cytosol cAMP levels4,10 Specific TxA2 receptors are coupled to adenylate 
cyclase via an inhibitory G-protein (G1). This stops the conversion of ATP to cAMP by the 
enzyme, thus inactivating a cAMP-dependent protein kinase. This kinase is thought to be 
responsible for phosphorylating a 24kD, membrane-associated Ca2+ pump, enabling it to 
take Ca2+ from the cytosol into the dense tubular system (see figure 1.2)4. The outcome is 
that cytosolic Ca2+ levels rise, causing shape change, the release reaction and aggregation. A 
second protein phosphorylated by the cAMP-dependent protein kinase is the myosin light 
chain kinase4. This phosphorylation decreases the activity of the myosin kinase, preventing 
shape change. Hence, lowering cAMP causes shape change by a second mechanism. 
Platelet activating factor (PAF) is a product of stimulated cells, paticularly 
polymorphonuclear leukocytes. The compound can mediate autotoxic reactions such as 
anaphylaxis and shock. Levels of this potentially lethal substance are regulated by serum and 
cellular acetylhydrolases which convert PAF to an inactive metabolite4. Platelets possess 
between 150-300 PAF receptors with a dissociation constant of Kd=1.36nM4. PAF appears 
to occur via the phospholipase C dependent release of IP3 and DG independent of ADP 
release and TxA2 formation4,13 This suggests that PAF causes an IP3-dependent opening of 
Cat+-channels in the 
12 
-- COZH 
Me Arachidonic acid 
. p_p . 
1 Cyclooxygenase (Aspirin inhibits) 
CO2H 
O" 
ý, 
Me 
O-O "H 
Illý 
R=H: PGH2 
R= OH : PGG2 
PLATELETS 
via 
O"ýýý R 
VASCULAR ENDOTHELIUM 
via 
~O"" 'R 
CO2H 
Cs H, I 
OR 
COZH 
2CsH11 
bH 
OH 
Thromboxane AZ 
C02 H 
HO O- C5H, i 
(3 H 
Thromboxane BZ 
o- 
o- 
H 
MDA 
Prostacyclin (PGI2) 
H 
H11 
CI CO2H 
CsH>> 
OH HHT 
OH 
C02H 
CSH 
ÖH OH 
CO2 H 
PGF2a and other 
prostanoids 
FIGURE 1.4: The Biosynthesis of Thromboxane A2 
and Prostacyclin 
vti 
13 
platelet membrane or dense tubular system, mediating aggregation by directly raising Ca2+ 
levels 13 
Epinephrine is a very weak platelet agonist14. Its principal effect is to potentiate the 
effects of other agonists in vivo 15. Normal plasma contains approximately 2mM Ca2+, which 
appears to prevent epinephrine associating with platelet a2-adrenergic receptors 15. However, 
anticoagulated blood, with its reduced Ca2+, is able to sustain epinephrine-induced platelet 
aggregation. Platelets possess approximately 300 a2-adrenergic receptors each 
14. They are 
coupled to adenylate cyclase via the inhibitory Gi protein and cause activation in much the 
same way as TxA216. In addition, epinephrine in vitro appears to be a very strong stimulant 
of TxA2 synthesis, suggesting a link to phospholipase activities 16 
There are various mechanisms of coupling stimulus to response in platelets, that 
involve different "second messengers", formed in response to receptor occupation. These 
mediate the biochemical and morphological responses to agonists. One of the major second 
messengers in platelets is Cat+. Resting platelets have an internal calcium concentration of 
<O. lpM, compared to a plasma concentration of 2mM17. On activation, cytosolic Ca2+ 
levels rise rapidly , with associated thresholds for the various stages of platelet activation; 
shape change occurs at 0.8µM and full aggregation at 2µM cytosolic Cat+. 17 The Ca2+ 
comes from two sources, the plasma and from within the platelet itself. The major proportion 
of platelet Ca2+, some 60%, is stored in the dense granules, but this Ca2+, in common with 
that found in the mitochondria, has no role as a second messenger4. The internally released 
Ca2+ appears to come from the inner surface of the plasma membrane and the dense tubular 
system, from where it is released by 1P3. Plasma Ca2+ enters the platelet via ligand operated 
Ca2+ channels that appear to be dependent on ADP. Thrombin, ADP and PAF produce only 
small (5-lOmV) depolarisations of the platelet membrane, suggesting that these agonists 
promote Ca2+ influx via receptor-operated channels, not voltage-gated channels 18. Much of 
the platelet cytosolic Ca2+ is bound to calmodulin, a low molecular-weight, calcium-binding 
protein that mediates the activation of myosin light-chain kinase4. Calmodulin is a subunit of 
this kinase which becomes activated when cytosolic Ca2+ levels are raised. Ca2+ is also 
required for full activation of platelet protein 
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kinase C, phopholipase C and phospholipase A2, but calmodulin does not appear to be 
directly involved in these activations4. 
Platelet membranes possess two major phospholipase activities, phospholipase C 19 
and phospholipase A24. Both hydrolyse inositol lipids which make up 5% of the total platelet 
phospholipid. The major inositol lipid is phosphatidylinositol (PIP), mainly in the form 
phophatidylinositol-4, phosphate (PI-4, P) although the phosphatidylinositol-4,5, diphosphate 
form (PI-4,5, P2) is also present (see figure 1.5). The major fatty acids found are stearic and 
arachionic acid at positions 1 and 2 of glycerol, respectively4. The phospholipases cleave 
PIP2 at the given positions to give the products shown below: 
PIP2 Phospholipase C, Ip3 + DO 
pIp2 Phospholipase A, Lysophospholipid + Arachidonate 
1P3 is membrane insoluble, and passes into the cytosol where it is essential for the 
release of calcium from intracellular stores. DG, in contrast is membrane soluble and serves a 
two-fold purpose20. Primarily it is the activator of protein kinase C, but it can also serve as a 
substrate for phospholipase A2, yielding arachidonate. Phospholipase C is activated directly 
by certain agonists through a G-protein link between the receptor and phosholipase C 19 By 
contrast, phospholipase A2 does not seem to be directly linked to a receptor-agonist complex, 
but rather is activated as a consequence of raised Ca2+ levels4. 
Arachidonate is the substrate for an enzyme cascade leading to the formation of TxA2 
(figure 1.4). In the presence of 02, arachidonate is converted to prostaglandin G2 by 
membrane-bound cyclooxygenase, a single 72kD polypeptide chain containing two distinct 
enzymatic activities, oxygenase and peroxidase21. The enzyme is self-destructive. It is 
rapidly and irreversibly inactivated by its products. Prostaglandin GZ is rapidly peroxidised to 
prostaglandin H2, which in turn is converted to TxA2 by thromboxane synthetase21. 
The third major pathway involved in platelet activation uses cyclic AMP. Platelet 
cAMP levels are controlled by two enzymes, adenylate cyclase and cAMP- 
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phosphodiesterase22. Adenylate cyclase prouces cAMP from ATP, and phosphodiesterase 
converts it to AMP. In resting platelets, cAMP controls cAMP-dependent protein kinases 
which in the presence of cAMP phosphorylate a 24kD protein believed to form part of the 
membrane-associated Ca2+ pump, and the myosin light-chain kinase4. These 
phosphorylations inhibit Ca2+ influx and shape-change, effectively preventing platelet 
aggregation. However, adenylate cyclase is also linked to receptors for agonists such as TxA2 
and epinephrine via an inhibitory G-protein23. On binding these agonists, adenylate cyclase 
is inhibited, cAMP levels fall and the activity of cAMP-dependent protein kinases diminish, 
allowing Ca2+ influx and myosin light chain phosphorylation. 
The phosphorylations caused by the kinases described leads to disassembly of the 
platelet microtubules and their subsequent reassociation. The myosin light chain is only 10% 
phosphorylated in resting platelets, but on platelet activation it becomes 100% 
phosphorylated within 30. seconds, causing association with actin4. This has a number of 
physical effects on the platelet. The platelets change shape, and actinomyosin filaments 
become associated with surface GP-1b and GP-Ub/GP-IIla4. Platelet granules migrate to the 
centre of the platelet, presumably due to links between these organelles and the actinomyosin 
filaments. Ultimately they release their contents into the surface-connected-canalicular 
system. Binding of fibrinogen and other adhesive proteins by the surface glycoproteins forms 
a physical link between platelet cytoskeletons and the fibrin network of clotting blood, via 
actin-binding protein, the receptors and adhesive proteins. This link is thought to play an 
important role in subsequent clot-retraction processes4. 
In addition to the complex platelet activation mechanisms discussed here it is 
important that aggregation should have a counter-regulatory inhibition mechanism, otherwise 
the smallest incidence of platelet activation would lead to a chain reaction of aggregation 
involving the entire circulation. A list of In vivo anti-aggregatory agents is given in table 1.2. 
Under normal conditions, endothelial cells present a non-thrombogenic surface to 
flowing blood7. A major role has been proposed for the endothelial glycocalyx. This consists 
of anionic glycoproteins and glycosaminoglycans that electrostatically repulse blood cells. In 
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addition, the vascular endothelium produces various enzymes with an ectonucleotidase 
activity that convert pro-aggregatory ADP to non-aggregatory ATP7. 
The major anti-aggregatory function of the vascular endothelium is to produce 
prostacyclin (PGI2). PGI2 is produced by a pathway analogous to that which produces TxA2 
in platelets (figure 1.4). The initial steps are the same as for TxA2 production, but vascular 
endothelial cells use the enzyme prostacyclin synthetase to produce PGI2 from PGH221. 
PGI2 is the most potent inhibitor of platelet function known4. It interacts with platelet 
membrane receptors of two types, a high affinity (Kd=12.1 nM) type with 93 sites per 
platelet, and a low affinity (Kd=0.9tM) type of 2700 receptors per platelet4. Both receptors 
are coupled via a stimulatory G-protein, Gs, to the same adenylate cyclase system as the 
TxA2 receptor. In contrast to TxA223, PGI2 activates adenylate cyclase, increasing cytosolic 
cAMP levels and preventing aggregation (figure 1.2). Endothelial cells constantly produce 
low amounts of PGI2, but to produce significant amounts of PGI2, endothelial cells must be 
stimulated by clotting factors or aggregation agonists such as factor Xa, thrombin and ADP7. 
In addition, endothelial cells are able to use platelet-derived endoperoxides for their own 
PGI2 synthesis, suggesting that the antithrombogenic activity of enothelial cells is amplified 
by activated platelets, causing a feedback inhibition of platelet aggregation7. Only at sites of 
endothelial damage, where the capacity to produce PGI2 is destroyed and adhesive fibres are 
exposed, should any major degree of p6telet aggregation occur. The effects of both PGI2 and 
TxA2 are extremely localised as each is rapidly metabolised to a non-active analogue, 6-keto- 
PGFI a and TxB2 respectively. 
Numerous proteins which bind and prevent the action of thrombin are present in 
plasma and on the enothelial surface. Antithrombin III is the principal plasma protein 
responsible for the inactivation of thrombin3'7, but other plasma proteins such as a2- 
macroglobulin and al-proteolytic inhibitor and endothelial proteins including 
thrombomodulin are also able to bind and inactivate thrombin7. 
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Much recent attention has been focused on the use of dietary fish oil supplements, and 
their beneficial effect in the prevention of cardiovascular disease24. Dietaryfish oils contain 
large amounts of w-3 polyunsaturated fatty acids, including linolenic acid (18 carbon, 3 
double bonds) which is processed via the cyclooxygenase pathway to give PGI3 and TxA3, 
analogues of PGI2 and TxA2 produced naturally from arachidonic acid (20 carbon, 4 double 
bond). In comparison to TxA2, TxA3 is a very weak platelet agonist, but the anti-aggregatory 
effect of PGI3, compared to PGI2 is reduced by a relatively small factor. Hence the balance 
favours platelet disaggregation, preventing inappropriate platelet activation. 
In contrast, platelet hypersensitivity appears to be enhanced by the incorporation of 
cholesterol into platelet membranes25. This event leads to the increased aggregation seen in 
platelets from sufferers of familial hypercholesterolemia26. 
Aspirin is a potent inhibitor of platelet cyclooxygenase, preventing TxA2 formation. 
The effect of aspirin on endothelial cyclooxygenase is comparatively small at low dose, 
hence the beneficial effects of low dose aspirin on cardiovascular patients2l. 
Evidence has been put forward to suggest a direct effect of exercise on platelet 
activation. Platelets from marathon runners 24 hours after a race show significantly greater 
PGI2 inhibition than non-runners27. This effect is not due to an increase in PGI2 receptors, 
but seems to be caused by a desensitisation by epinephrine of Gi, leaving more catalytic units 
of adenylate cyclase able to be stimulated by Gs27. 
Other known inhibitors of platelet function include; alcohol, vitamin E28, several 
antibiotics, indomethacin and dipyridamole. 
19 
1.6: Diabetes mellitus: Background. 
Diabetes mellitus affects 1-2% of the European population. It is not a single disease, 
but a collection of disorders with different treatments and pathologies, related by the presence 
of high concentrations of glucose in the blood (hyperglycaemia) due to a deficiency in the 
production or action of the hormone, insulin. 
The earliest description of the condition appears to be on the Elbers papyrus, dating 
from 1550 BC29, which outlines a treatment for polyuria. The term 'diabetes' refers to the 
excessive urination seen in the disease, and 'mellitus' comes from the latin, meaning 
'sweetened with honey'. The Greek, Aretaeus in the second century AD, described the 
condition thus29,30; 
"Diabetes mellitus is ..... a melting down of the 
flesh and limbs into urine ..... one cannot stop 
them from drinking or making water.... " 
This clinical description has been expanded over the years, but not surpassed. 
Aretaeus believed the disease to be triggered by the bite of a reptile, the Dipsas32, but the 
Indian, Susruta, writing in the sixth century, was closer to the truth claiming that diabetes 
mellitus was29; 
"A disease from which the rich principally suffer 
..... by their own overindulgence in rice and 
our..... . 
From the time of Galen, approximately 200 AD, the kidneys were believed to be the 
cause of diabetes mellitus29 and this theory persisted until 1679, when Thomas Willis stated 
that29; 
"We believe it to be more an affection of the 
blood rather than the kidneys caused by immoderate 
drinking..... or by sadness and long grief'. 
The first indication of the role of the pancreas came three years later, when Brumner 
noted that pancreatectomy in dogs led to polyuria32. However, most physicians still believed 
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the condition to be caused by the kidneys. Matthew Dobson, in the 1770's made several 
advances in the understanding of the disease. He evaporated the urine of a diabetic to give a 
'white cake' which29; 
"smelled sweet like brown sugar and tasted the same". 
He also noted the opaqueness of diabetic blood plasma, probably the first record of 
hyperlipidaemia together with hyperglycaemia29; 
"The saccharine matter was not formed in the kidney 
but existed primarily in the serum". 
Dobson was also the first to distinguish between type-1 and type-2 diabetes mellitus, 
noting that the disease could29; 
"..... terminate fatally in less than 5 weeks. In 
others it becomes a chronic complaint". 
A missed opportunity came in 1788 when Thomas Cawley noted that the pancreas of 
a diabetic was full of 'calculi'. Unfortunately, Cawley regarded this as an incidental finding 
and continued to blame the kidneys29. 
John Rollo in 1796 prescribed the first dietary intervention in diabetes mellitus. He 
advised a diabetic patient to have a diet of 'animal food', which incidently was very low in 
carbohydrate content29,30 As the patient was overweight, and probably a type-2 diabetic, he 
not surprisingly responded to the treatment, reinforcing Rollo's view that the stomach was the 
primary affected organ in the condition. 
The next major advance came in 1848 when Claude Bernard showed sugar to be 
formed endogenously by the liver, proposing that diabetes was due to faulty nerve control of 
the liver itself, resulting in too much sugar production29,32 
Paul Langerhans, in 1869, became the first to describe the pancreatic 'islets' that are 
now named after him32. Laguesse, in 1893, observed granules in the islets and suggested that 
they constituted an internal secretion29. Four years later, the classical depancreatised dog 
experiments of Minkowski and von Mering took place, leading to the devdopment of diabetes 
in the animals and strong evidence for the role of the pancreas in the condition 29,30,32 
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These observations led to the first attempts to produce an anti-diabetic pancreatic 
extract. De Witt in 1906, had some success with islet tissue from cats that was glycolytic in 
vitro29. In the same year, Zuelzer injected a pancreatic extract into a comatose, 50-year old 
diabetic, leading to an improvement that unfortunately was not sustained29. This extract, 
termed Acomatol by Zuelzer, was further purified and by 1911 had been shown to decrease 
acetone and sugar levels, but the side effects of the treatment were severe. Also in 1911, E. 
Scott prepared his own version of the extract by extracting the pancreas in alcohol29. This 
extract worked well on dogs, leading Scott to conclude that previous extracts had not been 
protected against oxidation or digestion by enzymes. Further improvements came with the 
work of Kleiner in 1919 and Paulescu in 192129. Kleiner's extract reduced blood glucose by 
up to 50% in 16 diabetic dogs. The only complication was a mild fever. Paulescu was able to 
lower glucose in both diabetic and normal dogs wiyh his extract known as Pancreine29. 
However, when used on patients, it caused irritation at the injection site leading Paulescu to 
attempt further purification. 
In the meantime, in Toronto, Banting and Best had begun their own experiments in 
the laboratory of Professor MacLeod, using the techniques developed by Scott29-32 fly 
results with experimental diabetes were good, but the first use of their extract, Isletin, on a 
patient, Leonard Thompson, was disappointing. Further purification of the extract, with a 
research biochemist named Collip, eventually led to retreatment of the same patient on the 
23rd of January, 1922 with great success. Shortly afterwards, the patent for the extract was 
given to the University of Toronto, and the drug company Eli Lilley took up the licence to 
produce the drug, now known as Insulin. 
1.7: Diabetes Mellitus: Pathogenesis and Treatment. 
The two types of diabetes mellitus have long been recognised. Lancereaux in 1880 
termed them diabete maigre (thin diabetes) and diabete gras (fat diabetes)30. The two types 
are now generally refered to as insulin-dependent diabetes mellitus (IDDM), or type-1 
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diabetes, and non-insulin-dependent diabetes mellitus (NIDDM), or type-2 diabetes 
respectively. The differences between the two conditions are summarised in table 1.3. 
Insulin is a protein hormone (molecular weight 6kD) which is synthesised by the ß- 
cells of the pancreatic Islets of Langerhans. It plays a major role in regulating the metabolism 
of carbohydrates, fats and proteins. The way insulin lowers blood glucose is particularly 
important and well understood. 
High levels of glucose, such as occur after a meal, cause the pancreas to secrete insulin 
which inhibits glucose output from the liver and stimulates glucose uptake by muscle and 
adipose tissue, where it is converted to the storage compound, glycogen. If blood glucose 
levels become too low, the body produces counter-regulatory hormones which oppose the 
action of insulin and thus prevent prolonged hypoglycaemia6. Epinephrine, released by the 
adrenal medulla, stimulates glycogen breakdown in muscle and glucagon, a polypeptide 
secreted by the pancreatic a-cells causes increased glycogen breakdown in the liver. The 
equilibrium set up by these hormones allows the maintainance of blood glucose levels within 
a narrow range. In healthy people the range is about 3.5-6.5 mM, but in diabetics, 
concentrations in the range 1.0-30.0mM have been observed35. 
Before the onset of effective treatment for diabetes, the lack of control of blood sugar 
levels was the direct cause of death in many diabetics34-36 Glucose is the major energy 
source for brain cells. Abnormally low levels of glucose starve the brain of energy and a state 
of hypoglycaemic coma ensues if the condition is poolonged36. On the other hand, 
hyperglycaemia causes unpleasant short-term symptoms such as frequent urination and thirst, 
and in the long-term may be a major factor in the development of tissue damage in the Ibod 
vessels, eyes, kidneys, nerves and elsewhere (see section 1.8). In addition, prolonged 
hyperglycaemia can also lead to coma. Because of the large quantities of sodium and water 
excreted to maintain the osmolarity of the blood, a fall in plasma volume and reduced cardiac 
output ensues. The outcome is that too little blood reaches the brain and, once again, coma 
follows35 
IDDM results from a decreased production of insulin by the pancreas. These patients 
have a greatly reduced (3-cell mass due to destruction of these cells by any of a number of 
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causes. Viral infections have been implicated as a major triggering factor for IDDM. It is 
known that an encephalomyocarditis virus36 can infect the [. -cells and other viruses 
implicated from epidemiological studies include; Coxsackievirus B, cytomegalovirus and 
those causing mumps, rubella, glandular fever and chicken pox36. However, not all people 
infected with these viruses become diabetic, suggesting a role for genetic factors. 
There is also strong evidence implicating autoimmunity as a cause for IDDM. Firstly, 
pathological studies of islet tissue from patients with IDDM have shown inflammatory 
lesions, characteristic of an immunologically mediated process36. Secondly, antibodies to 
islet cells have been found in diabetics at the time of onset of the disease36 and thirdly, 
lymphocytes from diabetics are cytolytic towards cultured human ß-ce1ls36. The third major 
trigger for IDDM is thought to be environmental toxins. However, as with viral attack, not all 
people exposed to potentially harmful chemicals become diabetic, again pointing to genetic 
factors. 
Heredity plays a complex and poorly understood part in the pathogenesis of diabetes. 
Diabetes tends to run in families, but less than 20% of patients have first-degree relations 
with a history of diabetes and studies with twins have shown that IDDM is concordant in 
only about 50% of cases36. Diabetics are known to have an increased frequency of certain 
major histocompatibility antigens35. These HLA (Human Leukocyte Antigens) are 
glycoproteins, present on all nucleated cells that determine the function of cytotoxic T- 
lymphocytes. Current thinking is that a tendency to develop diabetes is inherited, but that 
additional environmental triggers are necessary for the development of the disease. 
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VARIABLE IDDM NIDDM 
Age usually<40 usually>40 
Weight normal 60-90% obese 
Insulin need dependent(ketosis may require insulin 
without insulin) to control 
hyperglycaemia 
Diet adequate restrict 
kilocalories to kilocalories 
maintain weight 
Plasma glucose variable stable 
Plasma insulin low or absent low, normal or 
high 
Insulin receptors normal low or normal 
HLA high incidence of no correlation 
antigens B8, B 15, 
Dw3/DR3, Dw4/DR4 
Islet cell 50-80% positive antibodies less 
auto-antibodies at diagnosis than 5% positive 
at diagnosis 
Associated auto- present absent 
immune disease 
Vascular present present 
complications 
Incidence 10% of diabetes 90% of diabetes 
Table 1.3 Comparison of IDDM and NIDDM. 
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In contrast to IDDM, which can be controlled by insulin infusions, NIDDM patients 
have little use for such supplements. These patients possess an intact ß-cell mass but they 
show resistance to the action of insulin at the cellular level due to a decrease in the number of 
insulin receptors on target cells or to defective receptors 35. NIDDM is itself a group of 
diseases and other factors that may lead to similar consequences are; impaired glucose- 
stimulated insulin secretion from the pancreas, non-immunological insulin-antagonists in the 
circulation and increased hepatic glucose production30,35. Again, the exact causes of these 
types of diabetes are unknown, but NIDDM tends to develop in older, overweight patients. A 
genetic link is suggested by the observation that identical twins with NIDDM are concordant 
in 90% of cases. This genetic effect shows no correlation with HLA antigens30. 
Treatment of NIDDM takes the form of low-carbohydrate diet, often supplemented by 
oral hypoglycaemic agents, drugs which release insulin from the pancreas and augment its 
action at cellular receptors. Occasionaly, NIDDM patients are transfered to insulin when diet 
and oral agents fail to produce suffxent lowering of blood glucose. 
Prior to the advent of effective treatments for diabetes, diabetic coma was the major 
cause of mortality for diabetics34. By the 1920's, following the purification of insulin, its 
place as the leading cause of death was taken by cardio-renal vascular disease (figure 1.6)34 
As the development of insulins with prolonged action progressed and the life-expectancy of 
diabetics increased, diabetic vascular disease has become more and more of a problem, with 
the vas c ular complications having a longer period of time to fully exert its effects. Owing to 
the various types of vascular disease seen in diabetes, diabetics are twice as likely to suffer a 
heart attack or stroke than the general population, five times more prone to gangrene, 17 
times more prone to kidney failure and 25 times more likely to suffer blindness37. Indeed, 
diabetic retinopathy is the most common cause of blindness in people under the age of 65 in 
England and Wales36 
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As many as 45% of IDDM patients will develop some degree of kidney disease38. 
The healthy kidney acts as an excellent filtration system. The passage of molecules through 
the glomerular basement membrane is dependent upon size and electrical charge. Larger 
molecules will not pass through the pores, and negatively-charged molecules are less readily 
filtered than positively-charged ones. Damage to the glomerular filtration barrier can greatly 
alter its function, causing leakage of plasma protein and even erythrocytes into the urine. In 
healthy people, up to a gram of protein leaks through the glomeruli every 24 hours, but over 
95% of this is reabsorbed38. 
Glomerular filtration rate is elevated in the first few weeks after the development of 
diabetes. Early in the course of diabetes, excretion of urinary proteins spanning a molecular 
weight range of 44-l6OkD is significantly increased38,39 The principle proteins excreted are 
albumin, a negatively-charged 69kD molecule, and immunoglobin G (IgG), a neutral 
molecule of l6OkD38. These are characteristic of glomerular filtration malfunction, rather 
than tubular reabsorptive capacity, since the excretion of a2-microglobulin, a sensitive 
indicator of the latter process is normal41. Initial microproteinuria appears to be caused by an 
increased filtration pressure across the glomerulus, accompanied by a decrease in the level of 
negatively-charged sialic acid residues in the glomerular capillary walls38,39. 
As nephropathy progresses, glomerular filtration drops further as the number and size 
of pores in the glomerular membrane decreases, introducing a size-selectivity defect39. The 
increased glomerular permeability is accompanied by a thickening of the glomerular 
basement membrane (GBM)38-41 Progressive glomerular capillary occlusion due to 
continual thickening over many years ultimately leads to chronic renal failure. 
Numerous theories have been advanced to try to explain the development of 
nephropathy in diabetics. Only certain tissues require insulin for the intracellular transport of 
glucose. The kidney does not, and so tends to equilibriate with the extracellular glucose 
concentration«. Thus, hyperglycaemia causes increased glycosylation of GBM proteins, 
interfering with polypeptide packing and/or hydroxy-lysine derived cross-link formation39 
28 
This may result in an increased pore size. The excessive accumulation of GBM material seen 
in diabetes could represent increased synthesis, decreased degradation, or a combination of 
the two processes38. Alternatively, there could be a relative overproduction of certain 
basement membrane components. 
Diabetic retinopathy is characterised by a number of clinical manifestations which, 
together, tend to cover the light-sensitive cells of the retina. Clinically, diabetic retinopathy 
can be subdivided into38; 
(i) background retinopathy, 
(ii) maculopathy, 
(iii) proliferative retinopathy. 
Background retinopathy occurs in diabetics of any age and with any duration of 
diabetes. The condition involves retinal capillary haemorrhages, localised capillary dilations 
(microaneurysms), hard exudates and'cotton-wool spots'38,39. The exudates are most 
commonly found in the fibre layer of Henle, and consist of extracellular lipids, macrophages 
and amorphous extracellular fluid. Cotton-wool spots are white lesions made up of the 
distended stumps of ganglion-cell axons in the retinal nerve-fibre layer38. 
The term 'maculopathy' denotes actual visual loss due to increasingly serious oedema 
in the form of microaneurysms, haemorrhages and exudates in the region of the macula lutea, 
the yellow spot at which the retina has its highest visual acuity38. 
The essential feature of proliferative retinopathy is extraretinal neovascularisation. 
New blood vessels proliferate in response to localised regions of hypoxia caused by capillary 
closure, haemorrhage and the decreased oxygen affinity of diabetic erythrocytes39. 
Ultimately, neovascularisation can extend into the vitreous gel, causing detatchment of the 
vitreous gel from the retina. The detatched retina may become mis-shapen and, if there is 
associated haemorrhage, sub-retinal fluid may become blood-stained. Once the macula 
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becomes detatched, vision is profoundly affected and there may be a slow progression to 
complete blindness owing to atrophy of the detatched retina38. 
Diabetic neuropathy is characterised by a variety of morphological changes associated 
with decreased sensory and motor conduction velocities. The most frequent symptoms of 
diabetic peripheral neuropathy are numbness and paraesthesias. Potentially more serious is 
autonomic neuropathy. All tissues which receive autonomic innervation may be affected, 
these include the cardiovascular, alimentary and genito-urinary systems, sweating 
mechanisms and the pupils38. Cardiovascular neuropathy can lead to hypotension and loss of 
heart-rate variability. The commonest symptom of autonomic neuropathy is diarrhoea, but 
other rarer gastrointestinal disorders such as gastroparesis, oesophageal and gall bladder 
dysfunction have also been reported in diabetic neuropathy38. Autonomic neuropathy is the 
major reason for the increased incidence of impotence in diabetic males. With increasing age 
and duration of diabetes, the early symptoms of hypoglycaemia may be lost, and patients then 
suddenly lose consciousness without warning. This too may be a result of impaired peripheral 
and autonomic conductance38. 
Structural studies of peripheral nerves from diabetics characteristicly show segmental 
demyelination and shrinkage of axons and Schwann cells. In addition to these changes, 
abnormalities in neuronal vasculature also occur in diabetes39. Marked thickening of 
basement membranes surrounding intraneural and perineural vessels has been described in 
company with hyperplasia of endothelial cells in small vessels, occasionaly occluding the 
vessel lumen37. Abnormalities in the microvaculature of peripheral nerves may reduce blood 
flow through small vessels, producing regional ischaemia and microinfarcts that could 
contribute to neuronal dysfunction. 
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In addition to the virtually diabetes-specific, microangiopathic complications already 
described, large blood vessel disease (macroangiopathy) is also accelerated in diabetes39. 
Epidemiological data appears to show no excess risk from diabetes independent of 
hypertension, cigarette smoking and hyperlipidemia38. 
Cataract, opacity of the eye lens, occurs earlier in diabetics than in the general 
population due to the formation of high molecular weight lens protein aggregates39. Non- 
enzymatic glycosylation of lens proteins facilitates sulphydryl oxidation and the formation of 
inter-protein disulphide bonds. The lens, like other body tissues that develop diabetic 
complications, does not require insulin for glucose transport. Hence, hyperglycaemia would 
increase the concentration of glucose in the lens. 
1.9: Is there a Common Mechanism for the Development of Different Diabetic 
Complicate? 
The retina, nerves, blood vessels and renal glomeruli of diabetics all contain 
abnormally high levels of the sugar alcohol, sorbito139"40. Under normal circumstances, 
glucose is utilised by glycolysis. However, in the presence of very high levels of glucose, the 
pathway becomes saturated, and the excess glucose is metabolised by the polyol pathway 
(figure 1.7)'. This leads to a build-up of sorbitol and fructose in diabetic tissues such as 
nerves, the retina, lens and renal glomerulus where glucose uptake is not insulin-dependent, 
and high amounts of aldose reductase are present. 
Increased polyol pathway activity leads to an accumulation of sorbitol in the cell 
membrane, which affects the integrity of the membrane and the function of Na+/K+ ATPase 
trans-membrane pumps`. In nerve tissue, this slows conductance, in the kidney it increases 
the glomerular filtration rate and in the retina it affects the integrity of the blood-retinal 
barrier. The build-up of sorbitol can be slowed by the use of specific aldose reductase 
inhibitors. 
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Capilary basement membrane thickening is the hallmark of diabetic microangiopathy. 
This phenomenon is less severe with good metabolic control and the disorder appears to be a 
consequence of insulin deficiency rather than a seperately inherited entity. After five years of 
clinical diabetes, basement membranes are 25-30% thicker than in normal subjects (Osterby 
et al 1986)41. Non-enzymatic glycosylation of basement membrane collagen and laminin is 
postulated to play a major role in the thickening of basement membrane in conjunction with 
increased deposition of new membrane material39. 
Non-enzymatic glycosylation (figure 1.8) also affects a multitude of other proteins42. 
Typically, the life-span of glycosylated proteins is reduced. More specific effects include the 
inhibition of hepatic uptake of glycoproteins by glycosylated albumin42; the resistance of 
glycosylated fibrin to digestion42; the inhibition of endothelial cell production of PGI2 by 
glucose43; a decreased uptake of glycosylated LDL by cellsW; the increased 02 affinity of 
glycosylated haemoglobin (HbAic) and decreased red cell deformability due to glycosylation 
of membrane proteins42. All these factors have the potential to affect the development of 
microvascular disease. 
1.10: The Role of Platelets. 
As with other elements of the blood, platelets are prone to non-enzymatic 
glycosylation in diabetes. However, there appears to be no significant correlation between 
degree of platelet aggregation and platelet glycosylation'W. 
Various functional and biochemical abnormalities have been reported in platelets 
obtained from diabetics, including alterations in adhesion37, increased sensitivity to 
aggregation agonists and increased TxA2 production''50. However, extensive research in 
this field has provided inconsistent results and conclusions (review: Ostermann and van de 
Loo, 1986)45. Consensus results are that diabetic platelets show increased adhesion and 
aggregation in vitro, with the tendency towards abnormality increasing with age and degree 
of microvascular disease. Spontaneous platelet aggregation (SPA) in vitro is seen in many 
diabetics but is rare in healthy, young individuals47. The degree of SPA varies greatly 
between donors, and also appears to fluctuate with time in individuals. 
33 
VV 
c- 
I 
OH 
H 
I 
C! O + HN - It 
Glucose 
HIV`- C- CH 2 
Ii 0 
Ketoaminc 
NH -k 
II ti 
C-C--h-R 
mine ``ýcýý` 
Oil 
Schiffs Nase 
FIGURE 1.8 : The formation of glycosylated proteins 
34 
Strong evidence that SPA occurs in vivo in diabetics is discussed in several studies and 
inferred from raised levels of the platelet-activation markers, ß-thromboglobulin48,49, 
TxB250 and malondialdehyde (MDA)51 in diabetic blood plasma. 
Small platelet microaggregates may occlude the lumen of fine capillaries already 
reduced in diameter by capillary basement membrane thickening. These blockages would 
cause haemorrhage and localised hypoxia in the tissue served by the capillaries. Numerous 
observations have been made and theories advanced as to why inappropriate platelet 
activation should occur in diabetes. In addition to making abnormally high levels of TxA2, 
the response of diabetic platelets to the anti-aggregatory PGI2 is frequently reduced45, 
tipping the delicate haemostatic balance towards aggregation. Platelets from diabetics have 
also been shown to have an increased permeability to Ca2+, rendering them more prone to 
activation52. 
Platelet hyperactivity may be related to the quality of diabetic control. Poorly 
controlled diabetics tend to progress more rapidly towards microangiopathy, although this is 
by no means always the case. Evidence suggests that subcutaneous insulin infusion retards 
platelet aggregation more effectively ex vivo compared to platelets from donors using 
optimised conventional insulin therapy with its widely fluctuating insulin and glucose 
levels53. 
Chapter 2 
PLATELET CONCENTRATE STABILISATION 
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Severe thrombocytopenia, or low platelet count, can cause bleeding from small blood 
vessels, symptomatically seen as purpura and mucosal haemorrhage. Thrombocytopenia also 
carries the risk of bleeding from a major blood vessel, which could prove fatal. 
There are many causes for thrombocytopenia, but they can be divided into four 
groups3; 
(i) Thrombocytopenia due to diminished or defective platelet production such as in (a) 
amegakaryocytic thrombocytopenia or aplastic anaemia, or (b) in the wake of certain viral 
infections. 
(ii) Thrombocytopenia due to enhanced platelet destruction, caused by severe burns, 
drug hypersensitivitys or idiopathic thrombocytopenic purpura (ITP). 
(iii) Thrombocytopenia due to sequestration of platelets by the spleen, as occurs in 
hypersplenism or hypothermia. 
(iv) Thrombocytopenia due to platelet loss after haemorrhage, multiple blood 
transfusions, or extracorporeal perfusion. 
In general, platelet transfusion therapy is only of use in cases of defective or 
diminished platelet production, or platelet loss54. Platelets transfused into patients with 
thrombocytopenia due to sequestration or enhanced platelet destruction will suffer the same 
fate as the patient's own platelets. In addition, circulating platelets are young and 
metabolically active, so the risk of haemorrhage is small compared to other 
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thrombocytopenias. In these cases, platelet transfusion is only employed in the event of 
severe, life-threatening haemorrhage54. 
Platelet transfusion therapy can be used to prevent haemorrhagic death in patients 
with thrombocytopenia due to the failure of platelet production by the bone-marrow. Thus, 
transfusions are frequently used during intensive chemothrapy for acute leukaemia and for 
sufferers of aplastic anaemia3,54 In the latter condition, thrombocytopenia is more persistant 
and multiple platelet transfusions are necessary. This introduces the risk of platelet antibody 
effects. Hence, transfusions are used sparingly, and where possible with HLA-compatible 
platelets54. 
Multiple whole blood transfusions can cause dilutional thromocytopenia due to a 
replacement of viable platelets with non-viable platelets transfused in with the stored blood 
samples3. For this reason, platelets are routinely transfused after each 10-12 units of whole 
blood. Similarly, extra-corporeal perfusion can cause a 50% drop in platelet number in 
patients undergoing surgery assisted by perfusion. This is due to platelet damage and loss 
within the perfusion apparatus itself3. 
In order to transfuse a large enough number of platelets to prevent haemorrhage, it is 
necessary to pool platelets from several donors and to concentrate the platelet-rich-plasma 
(PRP) so obtained four-fold. 
The high-speed centrifugation and pelleting of platelets involved in the preparation of 
platelet concentrates invariably leads to some degree of platelet activation and aggregation. 
Evidence of this is the presence of platelet activation markers in the plasma of both stored 
and fresh platelet concentrates. ß-thromboglobulin ((3-TG)68,69, a marker of the release 
reaction, and TxB269, the degradation product of the pro-aggregatory TxA2, synthesised and 
released by activated platelets, are both found at abnormally high concentrations even in 
apparently "good" quality concentrates. The cytoplasmic enzyme, lactate dehydrogenase55 is 
also found in platelet concentrates, demonstrating that platelet lysis, as well as conventional 
37 
activation mechanisms, plays a role in the "storage lesion" of platelet concentrates. Abundant 
amounts of platelet factor 3 (PF3)56 are found in stored concentrates. This factor possesses 
prothrombinase activity, thus increasing the likelihood of thrombin generation in the 
concentrate. Further evidence for the role of thrombin in platelet damage is given by the 
presence of fibrinopeptide A (FP-A), a peptide cleaved from fibrinogen by thrombin, in the 
plasma of blood products collected for transfusion57. 
Numerous studies have been undertaken to attempt to improve the quality and extend 
the shelf-life of platelet concentrates. These have included varying storage medium58, 
nutrients59'60, storage temperature61,62 and even the type of container59. 
Polyolefin plastic bags are now preferred to polyvinylchloride bags for the storage of 
concentrates, due to the enhanced gas permeability of the former, which prevents plasma 
becoming anoxic59. Storage at room temperature with gentle agitation gives a better 
preservation of platelet morphology and increased survival time than cold storage or storage 
at body temperature62. Progress has also been made in the development of non-plasma media 
for storing platelet concentrates58 and in adding platelet aggregation inhibitors to PRP prior 
to concentrate preparation68-70 
Despite these improvements, platelets in stored concentrates rapidly lose their ability 
to aggregate in the presence of physiological agonists in vitro, although transfused platelets 
do seem to recover functionality to some degree59"60, presumably due to replenishment of 
platelet metabolites from the patient's plasma. 
To meet demand for platelet concentrates, some centres prepare concentrates from 
over 50% of the units of whole blood obtained. Fewer platelet concentrates would be needed 
if activation and loss of function associated with preparation and storage of platelets could be 
reduced. Thus, it makes good clinical and economic sense to find ways in which platelet 
survival in vitro can be extended, or to improve the quality of platelet concentrates so that 
fewer transfusions are needed to achieve haemostasis. 
To this end, I have studied the effects of various anti-aggregatory reagents, either 
individually or in combinations, on the preparation and survival of platelet concentrates. 
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2.2; Methods. 
450m1 whole blood was collected, with informed consent, from healthy adults into 
plastic bags containing CPDA-1 anticoagulant ('Biopack'-Biotest Pharma Ltd. ). Platelet-rich 
plasma (PRP) was separated from whole blood by centrifugation at 1000g for 7 minutes at 
room temperature, as soon as possible after phlebotomy. PRP from four or five ABO- 
matched donors was pooled and separated into roughly equal aliquots of 250-300m1. Sterile 
sampling site couplers (Fenwall Laboratories, USA) were attatched to the PRP bags for 
addion of 'preservatives' and withdrawal of samples. Sterile platelet antagonists were added at 
this point using sterile syringes and needles. 
Platelet concentrates (PC) were prepared by centifuging PRP at 3500g for 7 minutes 
so that all but 70-80m1 of plasma was transferred to a second container, leaving pelleted 
platelets. 
The PC were left to stand for 30 minutes, then gently agitated for 15 minutes before 
being placed in an incubator shaker (LH Engineering Ltd. ) at 22°C, 10rpm. 
Initial preparative work was performed at the Regional Blood Transfusion Centre, 
Queen Elizabeth Hospital, Birmingham by Dr. Richard Daw and staff. 
Samples of PC were taken at various times using sterile syringes and needles. 
Samples thus obtained were tested for functionality, platelet number, pH and, where possible, 
for released ß-thromboglobulin (0-TG). 
Functionality was tested using a specially adapted MSE "Spectroplus" 
spectrophotometer, fitted wj th a cuvette holder with a magnetic stirrer base. 0.25ml of PC 
was diluted with 0.75m1 of autologous platelet poor plasma (PPP) to give a platelet count 
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similar to that seen in PRP. All cuvettes and magnetic stirrers were siliconised using 
'Sigmacote' (Sigma Ltd. ) prior to use to prevent interaction between their surfaces and 
platelets. Platelet activation, on the addition of agonist was measured by the decrease in 
optical density of the stirred sample at 600nm and 30°C. A stirring speed of 500rpm was used 
(see appendix 1, Platelet Aggregometry). 
Platelet counts were performed on either the Technicon H* 1 or Technicon H-6000 
automated haematology analyzers at the Coventry and Warwickshire Hospital. 
pH was measured using an EIL 7030 pH meter and electrode (Kent Industrial 
Measurements Ltd. ) 
The Amersham radioimmunoassay for (3-TG was used to test for the release of the 
protein from platelet dense granules. iml samples of PC were taken at various times and 
PGE1, a more stable analogue of prostacylin, was added to a final concentration of 1µM, 
more than sufficient to prevent further platelet activation during sample preparation. The 
samples were centrifuged at 10,000g for 3 minutes in a MSE Microcentaur. 0.5m1 aliquots of 
the resultant platelet free plasma were removed and frozen at -20°C. All samples collected 
during the PC stability study were then assayed by comparison with a (3-TG standard curve 
using the Amersham kit and recommended assay protocol. 
The assay protocol was as follows; 
(3-TG Standards (ng/ml) Unknowns 
(Sample no. ) 
10 20 50 100 225 1 2etc. 
Tube Number 1,2 3,4 5,6 7,8 9,10 11,12 13,14 
Standard Solutions 50 50 50 50 50 - - 
Unknown Solutions - - - - - 50 50 
1251-labelled 13-TG 200 200 200 200 200 200 200 
Anti-13-TG Serum 200 200 200 200 200 200 200 
Table 2.1: Contents of frTG assay tubes (all volumes in microlitres. ) 
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All tubes were vortex mixed and set aside to incubate at room temperature for one 
hour. 
0.5 ml of the kit ammonium sulphate solution was added to each tube, and the contents mixed 
and centrifuged at 1000-1500g in an Eppendorf 5415c microcentrifuge. 
The supernatant liquids were decanted and the tubes gently inverted so as not to 
disturb the precipitate, and placed so that they drained onto paper tissue for 5 minutes. 
The amount of radioactivity present in each tube was assessed using a gamma 
counter. 
Prostaglandin E1 (Sigma) 
Stored as 0.5mM stock solution in 50% Ethanol at -20°C. Diluted to an appropriate 
concentration in saline prior to use and filter-sterilised. 
Verapamil Hydrochloride (Sigma) 
60mM solution in saline, prepared and filter sterilised just prior to use. 
Nifedipine (Sigma) 
60mM solution in dimethylsulphoxide, prepared just prior to use. 
Insulin (Novo) 
Monotard MC insulin-zinc suspension, 100iu/ml. 
Hirudin (Sigma) 
5u/ml in sterile saline 
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Adenosine diphosphate reagent (Sigma) 
Special platelet aggregation reagent, reconstituted with water to give a buffered 
0.2mM solution of ADP. 
Adrenaline (Epinephrine) reagent (Sigma) 
Special platelet aggregation reagent, reconstituted with water to give a buffered 
0.1mM solution of adrenaline. 
(3-Thromboglobulin Radioimmunoassay kit (Amersham International p1c. ) 
Adenine hydrochloride (Sigma) 
24mg/ml in sterile saline. 
2.3; Results. 
The reason for presenting the results of experiments separately in the following 
section is that although each experiment is entirely self-consistent, the quality of the initial 
PC in terms of free platelet number and aggregation potential varied tremendously. 
2.3.1: A study of the effects of PGE1 and Veranamil on PC preparation and 
PGE1 is a cheaper, more stable analogue of the physiological platelet aggregation 
antagonist, prostacyclin (PGI2). It interacts with the prostacyclin receptor, causing activation 
of adenylate cyclase, raising platelet cAMP concentrations and thus rendering them less 
susceptible to activation and aggregation4. 
Verapamil inhibits platelet aggregation by blocking Ca2+ influx from plasma and 
release from internal stores. These effects maintain a low internal Ca2+ concentration, even 
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in the presence of platelet agonists78-83. In vitro, verapamil also appears to antagonise 
platelet a2-adrenergic receptors, thus directly inhibiting epinephrine-induced aggregation82. 
PGE1 and verapamil have been shown to synergisticly inhibit platelet aggregation78. 
Therefore in this initial study, the separate effects of PGE1, verapamil and a combination of 
the two were investigated when they were added to PRP just prior to the preparation of the 
PC. 
PRP was prepared and divided into dui equal aliquots and treated with 
"preservatives" to give the following PC preparations: 
(1) PC ; Control platelet concentrate. 
(2) PC+PGE1 ; Platelet concentrate containing 6OnM PGE1. 
(3) PC+PGE1+V ; Platelet concentrate containing 6OnM PGE1 and 200 M verapamil. 
Samples were taken 2 hours after preparation, and at 3 and 6 days, and assayed for 
pH, functionality and platelet number. 
DAY PC PC+PGEI PC+PGEI+V PPP 
0 7.6 7.6 7.6 7.6 
3 7.7 7.6 7.6 7.8 
6 7.6 7.7 7.6 8.1 
Table 2.2: Variation of pH with time : Experiment 2.3.1 
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DAY PC PC+PGE1 PC+PGEI+V 
1 0.125 0.050 0.0 575 
3 0.050 0.033 0.0725 
6 0.0275 0.0275 0.0425 
Table 2.3 : Aggregation in the presence of 10jiM ADP (0 OD): Experiment 2.3.1(a) 
DAY PC PC+PGE1 PC+PGEI+V 
0 705 832 1050 
3 876 778 985 
6 861 711 885 
Table 2.4: Platelet count. (x109[ 3) : Experiment 2.3.1(a) 
These results are expressed graphically in figures 2.1-2.2. 
Excellent resuspension of the platelet pellet was observed in all three samples, and 
platelet numbers were maintained well over the 7 days of the study. 
By far the greatest degree of aggregation was observed in the control PC at day 1. 
However, the PC's response decreased by approximately 75% over the duration of the tests. 
In contrast, the two treated PC showed relatively little initial aggregation, despite similar 
platelet numbers, but were able to maintain this level of functionality throughout the period 
of testing. This suggests that the aggregation of the PC+PGE1 and PC+PGE1+V samples is 
being inhibited by the platelet antagonists present on the first day of study. 
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PRP was divided into three equal aliquots and treated with 'preservatives' to give the 
following platelet concentrates; 
(1) PC ; Control platelet concentrate, 
(2) PC+V ; Platelet concentrate including 2OOµM verapamil, 
(3) PC+PGE1+V ; Platelet concentrate including 6OnM PGE1 and 200pM verapamil. 
Samples were taken after 2 hours, 1,3,4,5 and 6 days and tested for functionality, 
pH, platelet number and released (3-TG. 
DAY PC PC+V PC+PGE1+V PPP 
0 7.5 7.6 7.55 7.5 
1 7.6 7.6 7.6 7.6 
4 7.8 7.65 7.7 7.9 
5 7.8 7.8 7.65 7.9 
6 7.8 7.65 7.7 8.0 
DAY PC PC+V PC+PGEI+V 
0 431 876 1025 
1 888 964 1011 
4 850 968 1025 
5 753 880 950 
6 651 799 905 
Table 2.6 : Platelet number (x109%tjg3) * Experiment 2.3.1(b) 
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DAY PC PC+V PC+PGEI+V 
0 0 0.055 0.025 
1 0 0.037 0 
3 0 0.032 0 
4 0 0.013 0.007 
5 0 0 0 
6 0 0 0 
Table 2.7 : Platelet a gr ga ion in presence of 2L? 1 ADP (AOD) : Experiment 2.3.1(b) 
DAY PC PC+V PC+PGEI+V 
0 0.032 0.175 0.150 
1 0.050 0.160 0.060 
3 0.037 0.125 0.110 
4 0.025 0.090 0.090 
5 0.015 0.055 0.074 
6 0.006 0.040 0.072 
Table 2 .8" Platelet a ion in presence of 10 M ADP (t1QD) " periment 
2.3.1(b) 
DAY PC PC+V PC+PGEI+V 
0 >8000 >6000 920 
1 >15,000 10,800 4800 
4 23,100 18,300 14,700 
5 27,000 20,500 14,500 
6 - 24,000 15,600 
Table 2.9: Released 0-TG. (ng/ml PQ: Experiment 2.3.1(b) 
These results are expressed graphically in figures 2.3-2.6. 
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FIGURE 2.3 : Platelet Count ; Experiment 2.3.1(b) 
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In contast to the first experiment, only the treated concentrates showed excellent, 
rapid resuspension. The control PC achieved approximately 45% resuspension in the 2 hours 
following preparation, recovering to almost 90% at 24 hours. All three samples show a 
progressive loss of discrete platelets (approximately 10%) over days 4-6. 
The relatively poor resuspension of the untreated PC is mirrored in the results of the 
functionality tests. The treated samples show a much higher degree of aggregation after 2 
hours and, although platelet functionality in PC recovers as platelet number increases, the 
quality of the PC+V and PC+PGE1+V samples is always greater. The sample treated with 
both verapamil and PGE1 again shows an inhibition of aggregation up to day 3. This must be 
due to the presence of PGE1, possibly acting synergistically with verapamil, since verapamil 
alone does not exert this effect. 
The ß-TG assay clearly demonstrates the benefit of PGE1 in reducing platelet damage 
during concentrate preparation. Whereas both the PC and PC+V samples show a large release 
of ß-TG into plasma in the day 0, t=2 hours sample (>300x normal plasma levels), the 
P+PGE1+V sample shows a comparatively small release ( >35x normal plasma level). 
This study was a repeat of experiment 1, except that more time points were obtained, 
and ß-TG was assayed. 
DAY PC PC+PGE1 PC+PGEI+V PPP 
0 7.6 7.65 7.65 7.6 
1 7.55 7.65 7.7 7.6 
3 7.6 7.6 7.7 7.75 
5 7.65 7.7 7.65 7.95 
6 7.6 7.6 7.7 8.0 
Table 2.10 : Variation of nH with time : Experiment 2.3.1(c) 
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DAY PC PC+PGE1 PC+PGEI+V 
0 1012 1173 1540 
1 1203 1109 1402 
2 1271 1187 1551 
3 1256 1181 1555 
6 1223 1060 1560 
7 1068 1062 1378 
Table 2.11: Platelet number (x109[}3) 1 Experiment 2.3.1(c) 
DAY PC PC+PGE1 PC+PGE1+V 
0 0.140 0.090 0.075 
1 0.062 0.010 0.010 
2 0.045 0.010 0.035 
3 0.030 0.025 0.040 
4 0.016 0.014 0 
5 0.015 0.012 0 
6 0.008 0.025 0 
Table 2.12: Platelet aggregation in =sence of" ADP. (DODO ): Experiment 2.3.1(c) 
DAY PC PC+PGE1 PC+PGEI+V 
0 0.295 0.204 0.225 
1 0.240 0.175 0.165 
2 0.200 0.160 0.205 
3 0.180 0.185 0.275 
4 0.140 0.190 0.160 
5 0.116 0.145 0.025 
6 0.075 0.160 0 
7 0.009 0.080 0 
Table 2.13 : Platelet aggregation in presence of 10gM ADP. --(DOD) ; Experiment 2.3.1(c) 
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DAY PC PC+PGE 1 PC+PGE 1 +V 
0 15,500 2100 1100 
1 22,200 7650 11,400 
2 25,750 7750 8000 
3 20,400 14,100 9300 
6 28,200 27,000 21,000 
These results are expressed graphically in figures 2.7-2.10. 
This repeat of experiment I gave very similar results to the earlier test. Again, all 
three samples showed excellent resuspension and maintainance of platelet number. Equally, 
the inhibition of aggregation over the first few days is once again evident in the treated 
samples. 
Samples PC+PGEI and PC+PGE1+V did not show the massive initial release of ß- 
TG observed in the control sample, untreated PC, confiming the results of experiment 
2.3.1(b). This demonstrates that even though the PC platelets resuspended very well, they had 
undergone considerable, reversible activation during the preparative procedures. 
The behaviour of the PC+PGE1+V sample in functionality tests is most peculiar. 
Initial inhibition of aggregation disappears by day 3, at which point aggregation potential 
appears to be maximal, but this is followed by a complete loss of activity within the next 48 
hours. This may be due to accidental bacterial contamination of the concentrate during 
sampling. 
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2.3.2: The effect of a lower dose of PGE1 and a comparison between the calcium- 
channel-blockers. Verapamil and Nifedipine. 
Owing to the apparent inhibition of platelet aggregation at days 0-2 in the previous 
experiments, it was decided to reduce the concentration of PGE 1 in the concentrates in order 
to try and minimise the inhibition of aggregation in treated samples in comparison with any 
control PC that give good resuspension. 
In addition, a second Cat+-mobilisation inhibitor, nifedipine, was investigated. 
Nifedipine, under the trade name Adalat, is one of the most common drugs prescribed for the 
treatment of hypertension35 
PRP was split into four aliquots and treated to give the following PC samples; 
(i) PC : Control platelet concentrate. 
(ii) PC+PGE1 : Platelet concentrate including 15nM PGE1. 
(iii) PC+PGEI+V : Platelet concentrate including l5nM PGE1 and 200µM verapamil. 
(iv) PC+PGEI+N : Platelet concentrate including l5nM PGE1 and 200µM nifedipine. 
Samples were taken after 2 hours, 1,3,4,5 and 6 days and tested for pH, platelet 
count and functionality. 
DAY PC PC+PGE1 PC+PGE1+V PC+PGE1+N PPP 
0 7.55 7.60 7.60 7.65 7.50 
1 7.60 7.65 7.60 7.65 7.60 
3 7.60 7.65 7.60 7.65 7.60 
4 7.55 7.65 7.70 7.70 7.80 
5 7.60 7.70 7.70 7.75 7.85 
6 7.65 7.65 7.65 7.80 7.90 
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DAY PC PC+PGE1 PC+PGEI+V PC+PGEI+N 
0 175 885 911 1235 
1 661 875 830 1214 
4 597 904 820 1130 
5 572 809 771 826 
6 526 747 728 791 
Table 2.16: Platelet number (x109(m3) : Experiment 2.3.2. 
DAY PC PC+PGE1 PC+PGEI+V PC+PGEI+N 
0 0 0.070 0.110 0.020 
1 0.022 0.050 0.050 0 
3 0.002 0.020 0.012 0 
4 0.005 0.012 0.012 0 
5 0 0.012 0.027 0 
DAY PC PC+PGE1 PC+PGEI+V PC+PGEI+N 
0 0.015 0.220 0.220 0.080 
1 0.070 0.160 . 163 0.035 
3 0.040 0.080 . 085 0.010 
4 0.027 0.078 
. 080 0 
5 0.025 0.095 ). 115 0 
6 0.015 0.050 ). 075 0 
Table 2.18: Platelet aggregation in presence of 10uM ADP (4-OD): Experiment 2.3.2. 
These results are expressed graphically in figures 2.11-2.13. 
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The quality of platelet concentrate preparation in this experiment was similar to that 
achieved in experiment 2, and the control PC showed very similar patterns of resuspension 
and aggregation. 
The lower dose of PGE1 employed in this experiment appears to be sufficient to give 
rapid resuspension, and the inhibition of aggregation observed in experiments 1-3 over the 
first few days is not evident. Verapamil has no additional benefit compared to PGE 1 alone, 
since both aggregation and platelet numbers remained virtually identical. 
The most interesting results were obtained from sample PC+PGEI+N. A much higher 
initial platelet count was observed in this sample, but the response to ADP was greatly 
reduced. Both effects may be due to a combination of too high a dose of nifedipine, and the 
effects of dimethylsulphoxide (DMSO), used as a solvent for the drug. DMSO has been 
shown to inhibit platelet aggregation both in vivo and in vitro at the levels employed in this 
experiment63 (0.33% v/v in PC, 0.08% in aggregometry cuvette). However the increase in 
platelet number compared to the other treated samples indicates that l5nM PGE 1, even in the 
presence of verapamil, is not sufficient to resuspend all the platelets. 
Platelet concentrates, even in the presence of PGE1, use up virtually all of their 
glycogen stores within 4-6 days, independent of whether glucose is present in the storage 
medium or not59,70. Therefore, platelets in stored PCs must rely on their internal glycogen 
stores rather than external glucose as the fuel for metabolism and ATP production, and when 
this glycogen is consumed, they probably become non-functional. 
Platelets are known to possess insulin receptors103-106 and a glycogen synthase 
enzyme which can exist in two forms, the active I-form, and the D-form, which is inactive 
under normal physiological conditions3. Insulin converts the inactive to the active form. 
Hence, insulin was added to the PC to test the hypothesis that inclusion of insulin in the 
preparation of concentrates would prevent loss of glycogen stores and promote utilisation of 
external glucose. 
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PRP was split into four aliquots and treated to give the following platelet concentrate 
samples; 
(i) PC ; Control platelet concentrate. 
(ii) PC+PGE1 ; Platelet concentrate including 6OnM PGE 1. 
(iii) PC+1; Platelet concentrate including 0.3iu/ml Insulin. 
(iv) PC+PGE1+I ; Platelet concentrate including 6OnM PGE1 and 0.3iu/ml Insulin. 
Samples were taken after 2 hours and at 1,2,3,4 and 6 days after collection and 
tested for pH, platelet count and aggregation. Samples were also layered onto Percoll density 
gradients for ultra-centrifugation (see appendix 2 for method). 
The pH of all samples was 7.55 to 7.65 over the 7 days of testing. PPP was frozen and 
thawed just prior to use as a dilutant in functionality tests(pH = 7.60). 
DAY PC PC+PGE1 PC+I PC+PGEI+I 
0 115 842 103 867 
1 241 812 240 850 
6 363 728 717 741 
Table 2.19: Platelet count (x109/3) : Experiment 2.3.3. 
DAY PC PC+PGE1 PC+I PC+PGEI+I 
0 0 0.130 0 0.142 
1 0 0.055 0 0.045 
2 0 0.035 0 0.045 
3 0 0.035 0 0.040 
4 0 0.035 0 0.065 
6 0 0.030 0 0.047 
Table 2.20: Platelet aggregation in presence of 10L, M ADP (DOD) : Experiment 2.3.3. 
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These results are expressed graphically in figures 2.14-2.15. See figure 2.16 for 
buoyant-density centrifugation resuts. 
The quality of the initial, untreated concentrate preparation in this instance was very 
poor. The two samples prepared in the absense of PGE1 both showed only about 13% 
resuspension after two hours. Although the presence of insulin did seem to aid resuspension 
in the long-tens, neither sample showed any measurable response to ADP at any time during 
the experiment. 
Comparing PC+PGE1 and PC+PGEI+I samples, littleo6ditional benefit was observed 
in aggregometry experiments by having insulin present in addition to PGE 1. However, the 
density gradient centrifugation did provide some interesting observations. At day 1, the 
PC+PGEI+I sample gave the characteristic multiple banding seen in normal PRP. When 
investigated again on day 3, the intensity of the bands had decreased, although their positions 
were similar, and a small number of low-density platelet aggregates were seen. The pattern of 
bands and aggregates from the PC+PGE1 sample showed a major loss of the higher density 
bands, but no increase in platelet aggregates, despite the number of discrete platelets being 
similar to that in the PC+PGEI+I concentrate. The control and insulin-treated PC both gave 
high numbers of relatively large platelet aggregates, as would be expected owing to their 
poor resuspension. Despite the faintness of the bands in these two samples, many more were 
evident in the PC+I sample than in the control PC. The observation of a decrease in platelet 
density with storage time is in agreement with the discontinuous density-gradient work of 
Bolin et a164 who reported that the density changes were related to an alteration in platelet 
shape from discoid to spherical, and to an increase in size with storage time. 
Insulin appears to prevent this decrease in density suggesting that perhaps the 
platelets become lighter due to utilisation of glycogen stores. 
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Hirudin, a 65 amino acid polypeptide isolated from the parotid gland of the leech 
(Hirudo medicinalis), is the most potent natural inhibitor of coagulation known67. A very 
stable 1: 1 complex is rapidly formed with thrombin, therby abolishing its ability to cleave 
fibrinogen. Hirudin has also been shown to inhibit the thrombin-platelet interaction by 
interfering with the binding of thrombin to saturable, 'specific' receptors on the platelet 
surface, but not the nonsaturable, 'nonspecific' sites65. Hirudin also causes a rapid 
dissociation of thrombin bound to the saturable sites66. 
Considerable evidence has been gained in support of the hypothesis that thrombin 
generation plays a role in the 'storage lesion' of platelet concentrates. For these reasons the 
effect of hirudin on PC stability was investigated in the presence or absence of PGE 1. 
PRP was divided into four and treated with 'preservatives' to give the following 
platelet concentrate sampes; 
(i) PC ; Control platelet concentrate, 
(ii) PC+PGE1 ; Platelet concentrate including 6OnM PGEI, 
(iii) PC+H ; Platelet concentrate including 5 units/300ml Hirudin, 
(iv) PC+PGE1+H ; Platelet concentrate including 6OnM PGEI and 5 units/300ml 
Hirudin. 
Samples were taken at 2 hours, 1,3,6 and 9 days after collection and tested for 
platelet number, functionality and released 5-TG. 
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DAY PC PC+PGE1 PC+H PC+PGEI+H 
0 268 841 521 960 
1 702 743 749 895 
3 680 776 740 919 
6 688 801 699 886 
Table 2 . 21 " Platelet count (x 
109[ 3) : Experiment 2.3.4 
DAY PC PC+PGE1 PC+H PC+PGEI+H 
0 0.030 0.205 0.085 0.220 
3 0.055 0.138 0.054 0.152 
6 0.055 0.112 0.080 0.114 
9 0 0 0 0 
Table 2.22. -. Platelet aggregation in presence of 104 , 
b" DOD) : Experiment 
2.3.4" 
DAY PC PC+PGEI PC+H PC+PGEI+H 
0 15,800 420 11,500 150 
1 18,000 5420 11,500 2000 
6 22,000 6500 8750 11,500 
9 40,000 4700 30,000 18,300 
These results are expressed graphically in figures 2.17-2.19. 
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1000 
800 
a. ' 
ä 600 
r 1 
400 
200 
40 
32 
a 
24 
V 
16 
0 
F8 
ýx x 
0123 ý+ 5 
FIGURE 2.18: ß-Thromboglobulin Rel 
Experiment 2.3.4. 
X 
IT 
0/ 12l456ý°9 
Pays from Collection. 
- -t KEY: PC+PGEI+H t 
PC+PGE1 : 0- -0 
PC+H ="-'-- 'ý 
PC - xX 
66 
1200 
t%\ FIGURE 2.19: Platelet Aggregation with 
1000 o`\l OµM ADP : Expt. 2.3.4. 
800 
600 
\\ 
4O0 
200 ý" 
0123v5 
Days from Collection. 
KEY: PC+PGE1+H = t-- -t 
PC+PGE 1 =O--O 
PC+H =t--- 
PC =x X 
67 
The untreated sample showed poor initial resuspension, but recovered well by 24 
hours. The presence of hirudin may have had some minor benefit towards resuspension, 
presumably acting by causing dissociation and inactivation of platelet-bound thrombin. 
No improvement in aggregation was obtained through the presence of hirudin. The 
data for (3-TG release shows, as expected, that PGEI protects against platelet activation 
during preparation. Hirudin alone is not able to do this, suggesting that thrombin does not 
play a major role in the preparative lesion. Evidence for the role of thrombin in the 
subsequent storage lesion is provided by the lack of ß-TG release in the PC+H sample 
between days 0-6. 
2.3.5.: The effect of multiple additions of PGE 1 on platelet concentrate stabilisation. 
PGE1 appears to be doublely beneficial to PC, greatly enhancing platelet 
resuspension and also inhibiting the storage lesion, despite the apparent inactivation of PGE1 
after 48 hours or so. Other platelet 'preservatives' seem to be of benefit mainly in the 
resuspension of platelet pellets. Thus, an experiment was devised to find out if boosting 
PGE1 levels after PC preparation would have any effect. 
Experiment 7 
The following platelet concentrate samples were prepared; 
(i) PC ; Control platelet concentrate, 
(ii) PC+PGE1: 1 ; Platelet concentrate including 6OnM PGE1, 
(iii) PC+PGE1: 2 ; Platelet concentate including 6OnM PGE1 and additional l5nM 
PGEI every 24 hours, 
(iv) PC+PGE1: 3 ; Platelet concentrate including 6OnM PGE1 and additional 30nM 
PGE1 every 48 hours. 
Samples were taken after 2 hours, 1,3,4,5,6,7 and 8 days from collection and tested 
for platelet number and response to ADP/ Fpine jlvine . 
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DAY PC PC+PGE1: 1 PC+PGE1: 2 PC+PGE1: 3 
0 239 784 722 736 
1 515 770 729 761 
3 480 771 660 680 
4 465 749 139 672 
7 414 644 0 539 
8 372 583 0 475 
Table 2.24: Platelet count (x 109[ 3) : Experiment 2.3.5. 
DAY PC PC+PGE1: 1 PC+PGE1: 2 PC+PGE1: 3 
0 0 0.200 0.189 0.178 
1 0.037 0.120 0.089 0.114 
3 0.035 0.072 0.069 0.060 
4 0.030 0.060 0 0.045 
5 0.029 0.082 0 0.052 
6 0.025 0.077 0 0.069 
7 0.016 0.073 0 0.060 
8 0.010 0.055 0 0.048 
Table 2.25 " Platelet aggmgation in presence of 5Jtjy, 1 ADP and 2.5MM Epinephrine (AOD): 
Experiment 2.3.5. 
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DAY PC PC+PGE1: 1 PC+PGE1: 2 PC+PGE1: 3 
0 0 0.135 0.100 0.108 
1 0.022 0.064 0.061 0.040 
3 0.015 0.048 0.035 0.025 
4 0.009 0.020 0 0.015 
5 0.014 0.030 0 0.024 
6 0.010 0.043 0 0.038 
7 0.009 0.035 0 0.023 
8 0 0.030 0 0.018 
Table 2.26: Platelet aggregation in presence of I OgM ADP (4 Q 
These results are expressed graphically in figures 2.20-2.22. 
Once again the untreated PC sample showed poor initial resuspension, but was able to 
recover to approximately 70% of platelet numbers in the PC+PGE 1 sample by 24 hours. 
Resuspension in all three PGE1 preparations is very similar. The rapid decrease in viable 
platelet count in sample PC+PGE1: 2 was probably due to bacterial contamination of the 
plasma caused by the repeated PGE1 infusions and sample taking. 
Until this event, all three PGE1-treated samples showed almost identical aggregation 
profiles, indicating that increasing the PGE1 level after the initial preparative steps has no 
beneficial effect. 
Menitove et a168-70 used CPD anticoagulant in the preparation of their PCs. The tests 
described here have all employed CPDA-1 anticoagulant which differs only in the presence 
of 277mg/dm3 adenine hydrochloride. Despite this seemingly small change in conditions, the 
PCs prepared with the latter anticoagulant have shown vastly improved functionality 
72 
compared to that observed by Menitove's group. Therefore it was decided to compare 
platelets concentrated in the presence of CPD with CPDA-1 concentrated platelets. 
The following platelet concentrate samples were prepared; 
(i) PC ; Control platelet concentrate (CPD), 
(ii) PC+PGE1 ; Platelet concentrate including 6OnM PGE1(CPD) 
(iii) PC+A ; Platelet concentrate including 277mg/dm3 Adenine hydrochloride 
(CPDA-1), 
(iv) PC+PGE1+A ; Platelet concentrate including 6OnM PGE1 and 277mg/dm3 
Adenine hydrochloride (CPDA-1). 
Samples were taken after 2 hours, 1,2,3,4,5 and 8 days and tested for pH, platelet 
number and functionality. 
The pH of all four samples was 7.60-7.65 at t=2 hours, showing that addition of 
adenine-HC1 had no detrimental effect. 
DAY PC PC+PGE 1 PC+A PC+PGE 1 +A 
0 310 1152 1098 985* 
1 658 1095 1112 950 
3 738 1053 1030 895 
5 702 990 975 910 
8 582 927 940 866 
Table 2.27 : Platelet count (x 109(¢3) : Experiment 2.3.6. 
* Sample PC+PGE1+A contained only 85% of the PRP of the other concentrates, 
hence the intial platelet count is lower. 
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DAY PC PC+PGE 1 PC+A PC+PGE 1 +A 
0 0.008 0.250 0.240 0.180 
1 0.035 0.195 0.185 0.160 
2 0.065 0.235 0.180 0.175 
3 0.050 0.195 0.155 0.140 
4 0.044 0.170 0.127 0.124 
5 0.035 0.160 0.095 0.120 
8 0.005 0.160 0.007 0.018 
(DO` Dperiment 2.3.6. 
DAY PC PC+PGE1 PC+A PC+PGEI+A 
0 0 0.125 0.195 0.095 
1 0.012 0.090 0.135 0.075 
2 0.020 0.115 0.120 0.095 
3 0.018 0.090 0.080 0.065 
4 0.022 0.082 0.065 0.070 
5 0.016 0.078 0.050 0.065 
8 0 0.075 0.004 0.015 
Table 2.29: Platelet aggregation in presence of 10g ADP (AOD)" 
These results are expressed graphically in figures 2.23-2.25. 
Surprisingly, the PC+A sample gave perfect resuspension, in contrast to the untreated 
PC control, which showed relatively poor recovery. The PC+A sample exhibited the steady 
decrease in functionality as previously seen with good quality PCs [experiments 2.3.1(a) and 
2.3.1(c)]. 
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Once more, evidence for initial inhibition of aggregation was seen in the PC+PGE 1 and 
PC+PGE1+A samples. 
The apparent protective efect of adenine during PC preparation may be due to 
competition between adenine and ADP for the platelet's ADP receptor. Plasma ADP could 
originate from the platelets themselves, or from erythrocytes during the preparation of PRP. 
2.4 General Conclusions. 
In the absence of platelet protecting agents, three types of platelet resuspension were 
observed; 
(a) Good resuspension: Observed in experiments 1,3 and 8 (CPDA), in which full 
resuspension was achieved within 2 hours. 
(b) Fair resuspension: Observed in experiments 2,4,6,7 and 8 (CPD), in which 
complete or satisfactory resuspension was achieved by 24 hours. 
(c) Poor resuspension: Observed only in experiment 5, where satisactory resuspension 
did not occur. 
The possible reasons for this variability in resuspension is discussed later. However, 
all 17 samples prepared in the presence PGE1 showed maximal resuspension within 2 hours, 
including the samples in which a second preserving agent (verapamil, nifedipine, insulin or 
hirudin) was present. 
Interestingly, some paired reagents gave superior resuspension to PGE1 alone, 
suggesting that PGEI is not able to fully dissociate platelet aggregates on its own. This could 
indicate the presence of a population of platelets particularly resistant to disaggregation, 
possibly bound to contaminant erythrocytes in the PC. 
Unlike PCs, in which the pH remains fairly constant, autologous PPP, used for 
dilutions prior to aggregometry, shows a steady rise in pH. The reason for this is unclear, but 
certainly the presence of platelets prevents this effect. This buffering capacity of platelets 
may be due to the presence of the platelet Na+/H+ antiport71. On activation, platelets 
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exchange cytosolic H+ for plasma Na+, raising internal pH and aiding cytosolic Ca2+ 
mobilisation. Thus, the absence of a significant rise in pH of stirred PCs may be due to an 
extrusion of H+ from the platelets themselves. Conversely, a small rise in plasma pH may 
induce the activation of the Na+/H+ antiport, forcing protons out of the platelet. In this way, 
the compensation for rises in plasma pH may provide a mechanism or the storage lesion of 
PCs. 
The inconsistency in quality of PCs could be due to antigenic interactions between 
pooled platelets from different donors. Although all donors were ABO-matched, all blood 
cells possess many other antigenic determinants. 
Another possibility is variations in the time between venupuncture and PC 
preparation. Owing to logistical difficulties in transportation of blood from collection centres 
to the Blood Bank for processing, it was not possible to ensure a constant duration of time 
pre-concentration. Very fresh whole blood samples will contain endogenous prostacyclin, 
which may give protection to platelets during PRP and PC preparation. Prostacyclin is 
rapidly degraded to inactive 6-keto-PGFla21 in plasma, and so PCs prepared slightly later 
may be more difficult to resuspend. 
Similarly, the inhibition of aggregation by 6OnM PGE1 disappears within 48 hours, or 
so, of PC preparation, as shown by the "recovery" of aggregation potential after 2-3 days in 
PGE1-treated PCs. Whether this is due to degradation of PGE1, or down-regulation of 
platelet PGE1 receptors is unclear. Evidence for the latter hypothesis is given by the 
observation that increasing the concentration of PGE 1 after the initial resuspension 
(experiment 7) had no effect on either inhibition of aggregation or prolongation of shelf-life. 
There appear to be two quite distinct problems in the concentration of platelets for 
transfusion, the "preparative lesion" and the "storage lesion". The preparative lesion occurs 
during the pelleting of platelets from PRP to give the platelet concentrate itself, and is almost 
completely abolished by the presence of PGE1. This lesion is characterised by massive (3-TG 
release, indicative of platelet activation and the release reaction, and may be due to small 
amounts of plasma ADP and other agonists, platelet-bound thrombin, or platelet-surface 
antigenic interactions between platelets from different donors. 
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The storage lesion, which is characterised by a small but steady decrease in platelet 
number and a loss of platelet activation potential, seems to be due to a combination of 
fluctuations in plasma pH, thrombin generation and depletion of glycogen stores. 
A third factor which must be taken into account is the "experimental lesion", which 
arises due to the repeated sampling of PCs and removal of up to 5m1 per day for testing. Not 
only does this increase the risk off bacterial contamination, but it steadily decreases the 
volume of plasma, relative to the volume of the container, increasing the likelihood of 
potentially damaging interactions between platelets and the container. 
Several authors have shown that platelets transfused into patients recover 
functionality to some degree59,69,70 The reason or this is uncertain, but it seems likely that 
platelets replenish spent metabolites and granule contents from the recipient's plasma. For 
example, the presence of insulin may trigger the platelets to synthesise more glycogen. 
Menitove et a168-7° reported that PGE1 reduced post-transfusion recovery of platelets in an 
experimental model, possibly due to a transient lowering of the platelet's threshold for 
activation following transfusion. Owing to these results, this group argued against the use of 
PGE1 as a platelet preservative70. However this group only report PCs showing good 
resuspension and claim a complete loss of responsiveness to 10µM ADP within 4 days, even 
in the presence of PGE1, and no significant difference in response to ADP/epinephrine 
between PGE1-treated and untreated samples68. These results contradict the results reported 
here. 
The general quality of PCs prepared by existing techniques is not really satisactory. 
Many preparations never reach full resuspension of platelets, and even good preparations 
only have a shelf-life of 5 days maximum. With resuspension difficulties, this leaves a useful 
life-time of as little as 2-3 days when they are suitable for transfusion. 
Addition of a suitable platelet antagonist to the anticoagulant would result in full, 
immeadiate resuspension. Hence, PCs could be used within hours of preparation, and have an 
extended shelf-life, with improved aggregation response for as long as 7 days in the case of 
6OnM PGEI. This period may be extended still further in the absence of the "experimental 
lesion". Thus, the useful life-time of a PC is more than doubled, and the waste of the few PCs 
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that never reach satisfactory resuspension is eliminated. Evidently, the savings that this 
would entail must be weighed against the cost of adding preservatives to PCs. 
Using prices obtained from the "Sigma" catalogue, the reagents used in the study 
would cost as little as; 
PGE 1,60nM = 13p/PC, 
Verapamil, 200µM = 16.5p/PC, 
Insulin, 100iu = 31p/PC, 
Hirudin, 5 units = 35p/PC. 
All the preservatives used are regularly prescribed drugs and show no deleterious 
effects in vivo at the levels used. 
Thus, further studies on the post-transfusion recovery of platelets treated with PGE 1 
(or PGEI plus a second platelet preservative, eg. Insulin), similar to those undertaken by 
Menitove et a168-70 should be undertaken to prove that PGE 1-treated PCs are at least as 
good as untreated PCs in clinical trials. If this proves to be the case, then the routine 
preparation of PCs in the presence of PGE1 could be of major financial benefit to the blood- 
transfusion service. 
Chapter 3 80 
THE THIOBARBITURIC ACID ASSAY FOR MALONDIALDEHYDE IN 
BLOOD SERUM 
3.1 Background 
Lipid peroxidation plays an important role in the biosynthesis of TxA2 in platelets 
(figure 3.1). Several lipid peroxides and hydroperoxides are formed as intermediates in this 
pathway. Overproduction of these may play a part in the onset of diabetic microangiopathy 
since secondary lipid peroxidation can cause damage to cell membranes and their associated 
enzymes and structural proteins73. 
A by-product of prostanoid biosynthesis is malondialdehyde (MDA)75. Hence, there 
is a permanent basal level of MDA in the blood, owing to the continuous low-level synthesis 
of prostacyclin and TxA2. However, during a thrombotic episode involving in vivo platelet 
activation, the levels of TxA2, and hence MDA, would be expected to rise transiently but 
dramatically. 
Several authors have reported increased TxA2 formation by diabetic platelets or an 
increased circulating level of TxA245,46. However, other groups report a decrease in TxA2 
by diabetic platelets45. Even so, the tendency towards thrombosis is increased because anti- 
aggregatory PGI2 synthesis is supressed, in diabetes, to a greater degree than TxA2 
synthesis45 
Radioimmunoassay kits for the detection of TxB2 (the more stable degradation 
product of TxA2) are available. However, the cost of this technique was prohibitive for a 
survey of this size. 
Yagi72-74 has described a simple, sensitive assay, capable of detecting nanomolar 
levels of MDA in serum. This technique was used to compare serum MDA levels of diabetics 
with and without microangiopathy, and non-diabetic controls. 
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3.2.1.: The Assay T 
MDA and certain lipid peroxides react with thiobarbituric acid (TBA) to give a red 
pigment75 (figure 3.2). When excited by light of wavelength 515nm, this adduct emits light 
at 553nm. Hence a simple fluorimetric assay for MDA is possible. 
Since other serum components are known to react with TBA74'76, serum lipids and 
proteins are isolated by phosphotungstic acid/sulphuric acid precipitation prior to exposure to 
TBA. In this way, water-soluble, TBA-reacting substances are eliminated from the assay. 
Optimum coloured adduct formation is obtained by incubating samples with TBA at 
pH 3.5,95°C for one hour. The coloured pigment is extracted with n-butanol, and its 
fluorescence intensity compared to that of a tetramethoxypropane (TMP) standard, which is 
quantatitively converted to MDA during the assay74. 
N/12 Sulphuric acid. 
10% Phosphotungstic acid solution (w/v). 
TBA reagent; Freshly prepared mixture of equal volumes of glacial acetic acid and 
0.67% TBA solution (w/v). 
n-Butanol. 
Stock TMP solution (0.5 nmol/ml). 
(a) 1.5ml of venous blood was collected into an Eppendorf tube. Serum was obtained, 
after clotting, by spinning for 10 minutes in a MSE microcentaur bench centrifuge. 
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(b) Duplicate 2Oµ1 serum samples were taken and put into separate 12.5m1 
polypropylene centrifuge tubes. 4m1 of N/12 sulphuric acid was added to each tube and the 
mixture was gently mixed by inversion. 
(c) To this mixture was added 0.5ml of 10% phosphotungstic acid. After mixing, the 
tubes were centrifuged at 3000rpm for 10 minutes at room temperature in a Sorvall GSA 
rotor. 
(d) The supernatant was discarded and the precipitate resuspended in 2m1 of N/12 
sulphuric acid and 0.3m1 of 10% phosphotungstic acid. After mixing, a second 10 minute, 
3000rpm spin was performed. 
(e) The second sediment was taken up in 4m1 of distilled water and I. Oml of TBA 
reagent was added. The tube contents were mixed and heated at 95°C for 60 minutes in a 
water/steam bath. 
(f) After cooling on ice, 5.0m1 of n-butanol was added, the mixture was shaken 
vigo rously, and then centrifuged at 3000rpm for 15 minutes in the Sorvall GSA rotor. 
(g) The alcohol layer (upper) was removed and taken for fluorimetric analysis on the 
Perkin-Elmer LS5 fluorescence spectrophotometer, at 515nm excitation and 553nm emission. 
The blank used was n-butanol, and a MDA standard was obtained by reacting 
0.5nmoles of TMP through steps (e)-(g). 
Results and Calculations24 
F= fluorescence intensity of standard, 
f= fluorescence intensity of sample, 
Serum [MDA] = 0.5 x f/F x 1.0/0.02 = f/F x 25 nmoles/ml serum. 
Eighteen assays, carried out simultaneously on a single 1.5ml blood sample, showed 
that the assay was consistent to within 5% reproducability (s. d. ). 
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GROUP AGE SERUM [MDAJ NUMBER OF 
nmoles/ml SAMPLES 
ASSAYED 
All non-diabetic 52.25+/-18.01 2.81+/-0.56 63 
controls 
Controls < 50 years 31.78+/-10.08 2.64+/-0.55 23 
Controls > 50 years 64.02+/-8.32 2.91+/-0.55 40 
All diabetics 55.68+/-12.28 2.89+/-0.99 63 
Diabetics, no 55.28+/-11.35 2.51+/-0.36 28 
complications 
Diabetics with 56.00+/-13.29 3.19+/-1.21 35 
complications 
Table 3 .1" Serum MDA levels of diabetics and controls (means +/- s . 
d. ) 
Serum was used in the assay, in preference to plasma, in order to measure the capacity 
of the donor's platelets to produce TxA2 (and hence MDA) on activation induced by the 
clotting of whole blood. Ex vivo plasma MDA levels would give an indication of in vivo 
TxA2 production, but could also be due to MDA produced as a by-product of prostacyclin 
production by vascular endothelial cells. 
Non-diabetic donors were selected to give an appropriate age-match with the 
diabetics. However, figure 3.3 shows that there is no significant correlation between serum 
MDA concentration and donor age (controls, correlation coefficient = 0.202, diabetics, 
correlation coefficient = 0.030). 
The diabetics in the survey show a similar range of serum MDA concentrations to the 
controls, with the exception of two patients with severe microangiopathy (see figure 3.4). If 
these two patients are discounted, the mean MDA concentrations in serum from diabetics 
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with complications falls to 2.90+/-0.51 nmoles/ml, the same as age-matched controls. Only 
these two patients show a significant increase in MDA compared to controls (p > 0.05). 
Thus it appears that, in general, there is no difference in the capacity of diabetics and 
non-diabetic controls to produce MDA, and hence TxA2, on clotting. 
The two abnormal results require some explanation. Both patients are IDDMs, in their 
50s, with extensive retinopathy and mild proteinuria. However, similar patients, and several 
diabetics with more severe complications did not show the elevated serum MDA levels. 
There are four possible mechanisms for the production of elevated MDA levels (see 
figure 3.5). 
(1) Overactive Phospholipase A2: Resulting in the production of elevated levels of 
free arachidonate and hence more TxA2 and MDA. 
(2) Overactive cyclooxygenase: Producing more PGG2 from the available 
arachidonate. 
(3) An increase in non-enzymatic peroxidation, due to elevated levels of oxygen 
radical species within the platelet. 
(4) Defective TxA2 synthetase, producing less TxA2, and hence allowing more PGH2 
to be non-enzymatically degraded to MDA. 
Mechanisms (1) and (2) would result in elevated TxA2 as well as MDA, whereas 
mechanisms (3) and (4) would lead to decreased TxA2 production, but increased MDA 
synthesis. 
The absence of an elevated serum MDA level in controls and the majority of diabetics 
tested could be due to the phenomenon being a transient malfunction in platelet metabolism, 
possibly induced by periods of poor diabetic control. A longtitudinal survey of poorly 
controlled diabetics, involving multiple blood samplings over a period of months, would give 
some indication as to the viability of this hypothesis. 
Chapter 4 
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THE EFFECT OF VERAPAMIL ON PLATELET AGGREGATION IN DIABETICS 
AND NON-DIABETIC CONTROLS. 
4.1 : Background 
An increase in the cytoplasmic free Ca2+ concentration is an essential component of 
platelet activation. Resting, unstimulated platelets have a free Ca2+ level of less than 
0.1µM 17. Stimulation of platelets by an agonist such as ADP or collagen causes a rapid 
increase in cytoplasmic calcium due to influx from plasma and release of stored calcium from 
sites within the platelets'7. This increase in calcium is directly or indirectly responsible for 
platelet shape change, the release reaction and aggregation (see section 1.4 for full 
explanation). 
The calcium-channel-blockers (CCBs) are a heterogeneous group of drugs that share 
the common characteristic of inhibiting the influx of calcium ions across the plasma 
membrane of excitable cells78 
83. Thus, CCBs are regularly prescribed for the treatment of 
angina and hypertension due to their ability to make the heart work more economically and 
cause vasodilation. 
Verapamil, marketed as Isoptin78, was the prototype which paved the way for all 
calcium antagonists subsequently introduced, such as nifedipine (Adalat), dilitazem and the 
dihydropyridines. Many groups have reported that CCBs are able to inhibit platelet 
aggregation in vivo as well as in vitro and prevent thrombosis in experimental models78-83 
Abnormal Cat+-handling has been proposed as a mechanism for abnormal platelet 
aggregation in arterial thrombosis85 and diabetes mellitus patients52. 
In order to test the viability of using CCBs as anti-thrombotic, and hence possibly 
anti-m icroangiopathic drugs in diabetes patients, a series of experiments were performed to 
establish the relative sensitivities of platelets from diabetics and healthy controls to one of the 
most commonly prescribed CCBs, verapamil. 
4.2 0 Materials and Methods 
4.2.1: Reagents 
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Adenosine diphosphate reagent (Sigma); 
Special platelet aggregation reagent, reconstituted with water to give a buffered 
0.2mM solution of ADP. 
Verapamil hydrochloride (Sigma); 
18mg/ml in saline (36.6mM). 
Calcium ionophore, A23187: calcium salt (Sigma); 
0.1mg/m1 in saline (0.2mM). 
4.2.2.: Methods 
PRP was prepared from citrated whole blood as described in appendix 1. 
Initial experiments involved investigating the effect of an increasing dose of A23187 
or verapamil on platelet aggregation in the Platelet Aggregometer at the Coventry and 
Warwickshire Hospital. This was achieved by adding increasing doses of the stock reagents 
to stirred Iml PRP samples at 37°C in the presence of 2µM ADP. (see figure 4.1). 
In order to establish whether there was any difference in the response to verapamil in 
diabetics compared to non-diabetic cotrols, the following experiments were performed. 
The degree of aggregation induced by 2µM and 10µM ADP was established, 10µM 
being sufficient to cause full aggregation in most donors. This data was expressed as "2/10 
ADP" aggregation ratio where; 
2/10 ADP =O Di of 2ýtM x 100% 
DOD in presence of 1 µM ADP 
The DOD in the presence of various doses of veraparnil was established, and the data 
processed to give two indications of the inhibitory potential of verapamil; AD50, the dose of 
verapamil required to give a 50% reduction in 2/10 ADP ratio, and AD 100, the abolition 
dose, at which verapamil completely prevented platelet aggregation in the presence of 2µM 
ADP (see figure 4.2). 
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4.3 : Results 
2/10 ADP ratio, AD50 and AD100 are tabulated together with aggregation type (see 
appendix 1), age and clinical details in tables 4.1 and 4.2. 
The reproducibility of the technique was tested by assessing the platelet responses of 
two young non-diabetic controls at 7 points over a 12 week period (table 4.1 and figure 4.3). 
The mean responses to ADP and verapamil of the diabetic platelets were calculated 
and compared with an age-matched control population (ie. without the younger, multiply- 
assayed donors). These results are summarised in table 4.3. 
DONOR AGE PLATELET AGGREGATION 2/10 ADP AD Sp AD100 
NUIVBEI TYPE WITH RATIO(%) ghnl V erap. 
(x10 /dm) 2µM ADP 
AJS 22 335 Reversible 39 n/a 205 
AJS 22 316 Reversible 52 15 275 
AJS 22 340 Reversible 38 n/a 255 
AJS 22 379 Reversible 44 n/a 280 
AJS 22 321 Reversible 42 n/a 195 
AJS 22 276 Reversible 45 n/a 220 
AJS 22 299 Reversible 37 fl/a 175 
MEAN- 323.7 Reversible 42.4 n /a 2293 
32.7 5.2 41.1 
GMW 24 499 Reversible 53 70 430 
GMW 24 503 Reversible 57 135 440 
GMW 24 489 Reversible 57 90 400 
GMW 24 448 Reversible 55 35 350 
GMW 25 443 Reversible 55 50 335 
GMW 25 397 Reversible 53 15 290 
GMW 25 385 Reversible 60 95 350 
MEAN 24. 452.0 Reversible 55.7 70.0 370.7 
+1- 
47.9 2.5 416 54.5 
RJB 22 435 Reversible 42 n/a 360 
RJB 22 420 Biphasic 79 205 470 
RJB 22 476 Bi phasic 68 130 410 
MEAN 22 443.7 RevJBiph. 63.0 111.7 413.3 
+/- 
29.0 19.0 103.7 55.0 
BEPS 48 392 Biphasic 73 120 375 
JF 60 315 Reversible 84 240 465 
DF 56 323 Irreversible 85 240 570 
DF 56 519 Irreversible 81 242 410 
KA 31 341 Reversible 29 n/a 320 
CC 68 236 Irreversible 85 310 830 
VC 63 469 Biphasic 86 245 640 
ALT 26 399 Biphasic 68 70 265 
Table 4.1: The effects of Verapamil on Platelet Aggregation in Non-diabetic Controls. 
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DONOR AGE TYPE PLATELET 
NUMBER 
(xlo /1) 
AGGREG 
TYPE 
2/10 ADP 
RATIO(%) 
AD5 p AD100 
g/ml Verap. 
A41 61 I+++ 395 Irrev. 96 290 610 
A41 61 1+++ 369 Irrev. 90 275 585 
A42 46 N+++ 427 Irrev. 82 210 500 
A43 71 1++ 260 Biph. 60 125 470 
A44 23 1- 337 Rev. 62 120 420 
A45 50 N- 281 Rev. 90 285 515 
A46 59 N- 362 Irrev. 90 180 400 
A47 59 1+ 306 Irrev. 83 355 650 
A49 48 N+ 305 Rev. 61 190 375 
A50 67 I++ 421 Irrev 94 225 480 
A51 60 N- 609 Rev. 45 n/a 425 
A52 50 N++ 502 Irrev. 78 190 380 
A53 30 I++ 652 Irrev. 81 130 345 * A55* 73 I++ 289 Irrev. 88 185 395 
A56 70 N++ 326 Rev. 59 105 330 
A57 59 N++ 378 Rev. 75 335 635 
A58 56 I+++ 329 Rev. 70 175 480 
* A59* 59 I+++ 568 Rev. 45 n/a 390 
A60 28 I- 288 Rev. 39 n/a 355 * A61 * 55 I+++ 205 Irrev. 96 345 525 
A62 48 N+ 241 Irrev. 100 260 480 
Table 4.2: The Effects of Verapamil on Platelet Aggregation in Diabetic Patients. 
KEY: * indicates patients taking the anti-hypertensive CCB, Adalat (nifedipine) 
"TYPE" refers to type of diabetes, 
N=NIDDM, 
I=IDDM, 
and to degree of microangiopathy, 
-= no microangiopathy, 
+= background retinopathy, 
++ = severe retinopathy, 
+++ = retinopathy and proteinuria. 
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NUMBER O AGE PLATELET 2/10 ADP AD50 100 
SAMPLES NUMBER RATIO g/ml Verapamil 
(x 109/1) (%) 
CONTROLS 8 51.0 374.2 73.9 183.4 484.4 
+/- 
15.1 90.4 19.3 107.0 186.7 
DIABETICS 21 53.9 373.8 75.4 189.5 464.0 
+/- 
13.6 120.3 18.5 108.0 96.1 
4.4.: Discussion 
Figure 4.1 illustrates the opposing effects of adding increasing doses of A23187 and 
verapamil to ADP-activated PRP samples. The ionophore is able to prevent the reversal of 
aggregation seen at low dose ADP in healthy controls, but does not cause the secondary wave 
of aggregation at the concentrations investigated. Verapamil, by contrast, turns irreversible 
aggregation into the spontaneously reversible aggregation characteristic of "healthy" 
platelets. 
The similarity between diabetics and age-matched controls in both their response to 
ADP and their inhibition of aggregation by verapamil, suggests that the calcium-dependent 
mechanisms of platelet activation are not perturbed in diabetes. This contrasts with the work 
of Bergh et a152, who reported that IDDM without clinical complications showed 
abnormalities in Cat+-handling, involving an increased Ca2+ influx and a protracted initial 
efflux. However, this survey involved the relatively long-term (15 minutes-2 hours) 
investigation of 45Ca2+ influx into unstimulated platelets, and the corresponding efflux. In 
the study reported here, all aggregation events are complete within 5 minutes of the addition 
of an agonist (ADP), as is the uptake and release of Ca2+ by the platelet. 
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Shanbaky et a185 demonstrated that elevated cytoplasmic Ca2+ in resting platelets 
was a major risk factor for arterial thrombosis, lowering the threshold for activation by 
physiological agonists. This was also found to be the case in diabetics. The results reported 
here indicate that diabetics, even with microvascular complications, do not show an enhanced 
platelet aggregation or a decreased sensitivity to inhibition by verapamil, suggesting similar 
resting Ca2+ levels in platelets from diabetics and age-matched controls. 
Thus, it appears that if enhanced platelet aggregation in vivo occurs in diabetics, it is 
not, in general, due to an elevated basal Ca2+ level. However, CCBs may still have a role to 
play in the prevention or treatment of diabetic microangiopathy. It is well documented that 
verapamil is able to reduce platelet aggregation in vivo, possibly acting synergisticly with 
PGI2 and other endogenous anti-aggregatorsgl. Verapamil appears to inhibit platelet 
activation by at least two mechanisms. In addition to its familiar effect of blocking Cat+- 
channels, it is able to block the a2-adrenergic receptor of platelets, thus directly inhibiting 
activation by epinephrine82'83. It has also been proposed that verapamil is an antagonist of 
platelet serotonin receptors8'. 
Even if the primary cause of platelet activation in vivo in diabetes is not an elevated 
basal Ca2+ level, treatment with CCBs would be beneficial in two ways. The tendency for 
platelets to aggregate in response to an in vivo stimulus would be diminished, reducing the 
chances of circulating microaggregates, and in addition, the CCBs vasodilatory properties 
would reduce the risk of any microaggregates causing a blockage. 
Possible evidence of the beneficial effect of CCB therapy in diabetes is provided by 
the results from patients already taking the drugs. Of the three patients in this survey taking 
Adalat, one (A59) shows a surprisingly low degree of platelet aggregation in response to 
ADP, considering the extent of microvascular complications. This may represent an 
improvement in haemostasis since the development of the complications. In addition, patient 
R13 (see section 6.3) shows an almost complete lack of response to 2µ. M ADP, which again 
may be due to Adalat therapy. However, not all diabetics on CCBs show this improvement in 
platelet status, and all the patients noted are already suffering from some degree of 
microangiopathy. 
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The only way to discover whether CCBs could have a role in the prevention of 
microangiopathy is to perform a long-term survey on a number of diabetics treated with or 
without CCBs starting prior to the development of microvascular complications. Such a 
survey was beyond the scope of this project. 
Chapter 5 
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DOES DIABETIC PLASMA CONTAIN A PLATELET AGGREGATION- 
ENHANCING FACTOR? 
5.1 : Background. 
Blood plasma contains numerous factors which potentially can induce the activation 
of platelets in vivo. In addition to the recognised clotting factors and platelet agonists 
involved in haemostasis45,90,91, "abnormal" agonists such as bacterial endotoxins92, 
autoantibodies93,94, soluble immune complexes95 and lipoproteins26,97 may modify 
platelet function. 
All of the above may be postulated to play a role in the development of circulating 
platelet microaggregates in diabetic patients. Diabetic patients are part: ularly prone to 
recurrent viral and bacterial infection. Gram-negative bacteria produce an endotoxin, 
lipopolysaccharide in nature6, that has been shown to activate platelets in whole blood in 
vitro92. This effect requires the presence of other blood cells in addition to platelets (see 
section 7.3.5. ) and may explain the thrombocytopenia seen after certain types of infection. 
Autoantibodies may arise in diabetics against infused insulin95, non-enzymatically 
glycosylated plasma proteins94 and cellular receptors94. Platelets are known to possess 
receptors for the Fc portion of immunoglobulin G (IgG)95 and the induction of platelet 
aggregation by soluble immune complexes is well known95'96. Numerous workers have 
shown significant increases in the level of soluble immune complexes in the plasma of 
diabetic patients45,95 
Diabetics have been reported to have higher than normal levels of pro-atherogenic 
low density lipoprotein (LDL), and low levels of anti-atherogenic high density lipoprotein 
(HDL)45,98,99 platelets possess specific binding sites for lipoproteins97' 
100. Lipoprotein 
binding changes membrane cholestrol content and platelet responses95'96. LDL increases 
thrombin-induced platelet aggregation, whereas HDL has the opposite effect. However, the 
direct importance of LDL on diabetic platelet activation is questionable. Non-enzymatic 
glycosylation of LDL is increased in diabetics, inhibiting its association with cellular 
receptors94. The resulting high levels of blood cholestrol become deposited in various 
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tissues, par+icularly the vascular lumen, making high plasma LDL an important factor in the 
development of atherosclerosis or macrovascular disease98'99. Recently, much interest has 
been focused on lipoprotein(a) [Lp(a)], a varient of LDL that promotes coagulation by 
competing with plasminogen 101. Lp(a) is increased in the plasma of diabetics where it may 
play a part in thrombogenesis101 
The most clear evidence for a factor in diabetic plasma that could influence platelet 
function, but was not found in non-diabetics, has come from the work of Levin et a1102 
They reported that the degree of irreversible aggregation of a normal donor's platelets after 
ADP stimulus was increased when additional diabetic plasma was present. This factor has 
been partially purified, has a molecular weight of 21kD, and may represent an activated 
coagulation component or a prostaglandin metabolism modulator, but its exact nature is 
unclear102 
The following experiments investigate the effects of mixing diabetic plasma with 
platelets from non-diabetics and vice-versa. 
5.2.: Materials and Methods 
5.2.1.: Reagents 
3.8% Tri-sodium citrate solution; 
Adenosine diphosphate reagent (Sigma); 
Special platelet aggregation reagent, reconstituted with water to give a buffered 
0.2mM solution of ADP. 
Hirudin (Sigma), 
5 units/ml in saline. 
Protein-A sepharose CL-4B (Sigma); 
100 
2mg protein-A per ml gel: One ml gel binds approximately 20mg of human IgG. 
Heparin-agarose (type II) (Sigma); 
Approximately 803 g/ml of packed gel. 
5.2.2.: General Method 
Citrate anticoagulated venous blood was obtained with informed consent from 
diabetic patients and non-diabetic controls. PRP and PPP were prepared as described in 
appendix 1. 
"Mixing" experiments were performed by adding 0.35m1 of non-diabetic PRP to 
0.65m1 of diabetic PPP (or vice-versa), in a siliconised aggregometry cuvette. Mixed samples 
were incubated at 37°C for varying times prior to the onset of aggregation induced by 2µM 
ADP and stirring at 1000rpm. 
t=0 samples correspond to the aggregation obtained with 0.35m1 PRP diluted with 
0.65m1 of autologous PPP. (see also figure 5.1). 
5.2.3. " Adaptations to general method to determine the nature of the aggrregation- 
enhancing factor in diabetic plasma. 
(i) In order to prevent platelet activation by thrombin, hirudin was added to certain 
experiments at a final concentration of 50 milliunits/ml plasma. 
(ii) IgG and soluble immune complexes were removed from plasma by passing Iml of 
PPP through a 2m1 Protein-A sepharose column prior to mixing with PRP in some 
experiments. 
(iii) lml of PPP was passed through a Heparin-agarose column to remove 
antithrombin III (ATIIl) from the plasma prior to mixing with PRP in certain experiments. 
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(a) Column Efficiency; The protein concentrations of PPP passed through each 
column, and of full PPP were assayed using the Lowry protein assay 147 and comparison with 
a bovine serum albumin standard curve. 
Duplicate samples at each of two different concentrations of plasma were assayed to 
give quadruplicate results. 
The protein concentrations were found to be; 
(1) Full plasma = 105.8 mg protein/ml PPP. 
(2) Plasma after Heparin-agarose = 75.8 mg protein/ml PPP. 
(3) Plasma after Protein-A sepharose = 55.2 mg protein/ml PPP. 
(b) Mixing Experiments; The results of mixing PRP and PPP from diabetics and 
controls are expressed graphically in figures 5.2a-5.2n. They are derived by measuring the 
change in optical density (DOD) at 600nm of diluted PRP samples after the addition of 2µM 
ADP (see figure 5.1). 
The increase in aggregation typically seen when control platelets are mixed with 
diabetic plasma is defined below, so as to normalise results; 
Increase = DODmax - LODt=o x 100% 
AODt-0 
The decrease in aggregation typically seen when diabetic platelets are incubated with 
control plasma is defined as; 
Decrease = AODt=p - DODmm x 100% 
eont=o 
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Where AODmax. = The maximum change in optical density in heterologous mixed 
samples on the addition of 2µM ADP. 
AODmm. = The minimum change in optical density in heterologous mixed 
samples on the addition of 2µM ADP. 
AODt-0 = The change in optical density in autologous diluted samples on the 
addition of 2µM ADP. 
If, conversely, diabetic platelets decrease in sensitivity to ADP on mixing with control 
plasma, or control platelets increase in sensitivity on mixing with diabetic plasma, the results 
derived as above are expressed as a negative number. 
(c) Control mixing experiments; The results of mixing PRP and PPP from two 
different non-diabetic controls to check if the effects seen in experiments 5a-5n are diabetes 
specific are seen in figures 5o-5q. 
Diluted'PRP, ! fixed PRF. 
0.35  l diabetic 0.35  l diabetic 
PRP, + PAp. 
0.65  1 d Labe tic 0.65  1 control 
PPP. PPP. - 
ltso 
1 
ap 
O. D. 
c time 
Mixed PRP. 
H 
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PRP. 4 
0.65 al control 
PPP. 
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EXPERIMENT CONTROL AGGREGATION 
INCREASE 
DIABETIC AGGREGATION 
DECREASE 
(a) GMW -(11.9)% A52 50.9% 
(b) AJS 32.1% A53 11.4% 
(c) AJS 123.5% A56 6.0% 
(d) GMW 38.5% A54 40.7% 
(e) GMW 0 XI 26.7% 
(f) AJS 19.0% X2 32.0% 
(g) AJS 79.2% X4 -(5.3)% 
(h) AJS 67.5% X11 9.1% 
(i) AT 0 X12 25.7% 
(j) AJS -(41.7)% X13 53.8% 
(k) AJS -(29.2)% X14 21.4% 
(1) AJS 20.5% X15 10.2% 
(m) AJS 93.3% X17 14.9% 
(n) GMW 110.9% X16 10.7% 
Mean +/- 35.8%+/- 22.0% +/- 
s. d. 52.0% 17.4% 
5.4.. Discussion 
In all cases except experiment 5n, the diabetic donor showed a higher initial 
aggregation prior to mixing than the young, healthy controls involved. This is to be expected, 
since the degree of aggregation in response to ADP is known to increase in diabetics, and 
also to increase with age. Although most of the diabetics were significantly older than the 
controls, the initial aggregation response was similar, and in addition, the degree of 
microangiopathy did not have a consistent effect on initial aggregation. 
105 
Non-diabetic, healthy control plasma reduced the aggregation of diabetic platelets in 
all but one case, 5g. In contrast, diabetic plasma caused an increase in non-diabetic, healthy 
control platelet aggregation in 9 cases, a decrease in 3 cases, and had no effect in two others. 
This suggests that diabetic plasma contains a "factor", absent in control donors, that 
can potentiate platelet aggregation. Alternatively, diabetics may lack a parjicular aggregation 
inhibitor that is present in control donors. However care should be taken in describing this 
factor as diabetes-specific since figures 5o-5q clearly show that mixing PRP and PPP from 
two healthy controls gives similar results, with the plasma from the control showing the 
greater degree of initial aggregation increasing the aggregation of the platelets from the 
control with less initial aggregation, and vice versa. 
Depletion of IgG decreases the effect of diabetic plasma on normal platelets (5c, 5d) 
but increases the effect of control plasma on diabetic platelets (5c). These results suggest that 
both diabetic and non-diabetic plasma contain IgG or immune complexes that can potentiate 
aggregation, since the presence of IgG-depleted plasma causes a reduced t=40 aggregation in 
both mixtures. 
Depletion of ATIII (5e-5g) or addition of hirudin (5h-5n) generally had no effect on 
t=40 aggregation, suggesting that the aggregation enhancing factor is not thrombin. However, 
in one experiment (5h), a major reduction in diabetic plasma -enhanced aggregation is 
obtained in the presence of hirudin, possibly indicating the presence of thrombin in this 
paticular diabetic patient's plasma. 
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Chapter 6 
THE EFFECTS OF INSULIN ON BLOOD PLATELETS 
6.1 : Back round 
114 
Numerous types of human blood cells have been shown to possess specific insulin 
receptors, including monocytes, lymphocytes and erythrocytes. Hajek et a1103 demonstrated 
that platelets also possess specific insulin receptors with a high affinity dissociation constant 
of Kd= 3x109 M-1, and 570 +/- 100 sites per platelet. These figures can also be expressed as 
approximately 25 sites per µm2 platelet surface area, a figure very similar to that seen in 
other blood cells. 
Udvardy et a1104 have shown that platelets from NIDDM patients possess far fewer 
insulin receptors, only 30 +/- 11 sites per cell, compared to 420 +/- 116 for the control donors 
in their study. The affinity of the platelet insulin receptor was also significantly reduced in 
NIDDM. 
Many receptors exert their actions through specific guanine nucleotide regulatory 
proteins (G-proteins). These G-proteins , upon interaction with an appropriate occupied 
receptor, bind GTP in order to attain an activated state capable of modulating the activity of a 
paticular effector system 105,106 
There is a large family of G-proteins associated with cells, some of which have a 
clearly defined function. Platelets are known to express the stimulatory G-protein, Gs, whose 
activity can be stimulated by prostacyclin and PGE1, the inhibitory G-protein, Gi, stimulated 
by epinephrine and thrombin, and a G-protein, termed Gp, which can stimulate inositol 
phospholipid metabolism triggered by agonists such as vasopressin and thrombin 
105 
Houslay et a1105,106 have suggested that insulin might affect certain tissues by 
interacting with G-proteins, since insulin is able to inhibit adenylate cyclase and activate a 
high affinity plasma membrane cAMP-phosphodiesterase in hepatocytes. They termed this 
paticular G-protein Gins 105. If insulin affects the equivalent platelet enzymes in the same 
way, it would cause a lowering of platelet cAMP levels and would, at an appropriate 
concentration, be expected to potentiate platelet activation. 
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However, several authors have reported that insulin is able to decrease platelet 
aggregation both in vivo and in vitro107-109, in response to ADP and other agonists, leading 
to the theory that hyperinsulinaemia reduces platelet aggregation in vivo when euglycaemia is 
maintained. A proposal arising from these studies was that increased aggregation and 
decreased disaggregation in diabetics may be due to defective enzyme activities in diabetic 
platelets that could be corrected by insulin 108 
Contrary to this idea, insulin concentrations are commonly above normal in NIDDM 
patients who are obese as well as in IDDM patients using insulin injections. It has long been 
hypothesised that high levels of circulating insulin are related to the development of 
atherosclerosis through its effect on the endothelial cells of the blood vessels, either by 
causing damage to the blood vessels, or by acting on other factors involved in the 
development of atherosclerosis such as lipoproteins and smooth muscle cell 
proliferation 110,111 The evidence in favour of the view that insulin is atherogenic comes 
mainly from epidemiological studies in diabetics and non-diabetics, but results have been 
inconsistentl 11. 
It was decided to investigate the effects of insulin on platelet aggregation in vitro with 
PRP from both diabetics and controls. With a view to the suggestion that insulin might act on 
platelets through a G-protein linked to adenylate cyclase, it was decided to include PGE 1 in 
the system. PGEI is known to exert its inhibitory effects on platelets via an activation of 
adenylate cyclase and an increase in cAMP4,112. This system is more akin to the 
physiological situation in which potential platelet agonists are balanced by antagonists such 
as prostacyclin. Previous studies have concentrated only on the effects of insulin alone on 
agonist-induced platelet aggregation in healthy controls. 
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6.2. ; Materials and Methods 
Adenosine Diphosphate Reagent (Sigma); 
Special platelet aggregation reagent, reconstituted with water to give a buffered 
0.2mM solution of ADP. 
Prostaglandin E1 (Sigma); 
Stored as a 0.5mM stock solution in 50% ethanol at -20°C. Diluted to 6yM PGEI with 
saline prior to use. 
Insulin (Sigma); 
From bovine pancreas, approximately 24 i. u. /mg. Suspended in saline prior to use to 
give stock concentrations of IOOµM and 1µM. 
6.2.2.: Method 
PRP and PPP were prepared as described in appendix 1. 
I. Oml PRP samples were placed in siliconised aggregometry cuvettes and pre- 
incubated at 37°C for 10 minutes. 
"Baseline" aggregation was measured by adding 1Oµ1 of the stock ADP solution to a 
PRP sample, stirring at 1000rpm, 37°C, and recording the resultant change in optical density 
at 600nm, DOD 1 (see figure 6.1). 
The inhibitory action of PGE1 was measured by pre-incubating a second I. Oml PRP 
sample with 30 or 6OnM PGE1 for 3 minutes prior to the addition of 2µM ADP (DOD2). 
The effect of insulin on the system was measured by adding either 10"6 or 10-8 molar 
insulin to a PRP sample and stirring for 3 minutes prior to the addition of PGE1 and 
subsequently ADP (AOD3). 
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Figure 6.1.: The effects of ADP. PGE1 and insulin on platelet aggregation. 
The degrees of aggregation in the presence of the various reagents were recorded 
and, in addition, the percentage inhibition of aggregation by PGE 1 was calculated according 
to the formula; 
PGE1 inhibition effect; -- LO9J21tP221 x 100% 
AOD1 
Also, the effect of insulin on PGEI induced inhibition of aggregation was evaluated 
to give a "degree of recovery" according to the formula; 
Insulin/PGE1 antagonism factor =AOD3=jOD2 x 100% 
AOD1-DOD2 
By this formula, an insulin-induced increase in aggregation will give a positive 
number, whereas a decrease will be negative. 
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Results are expressed in tables 6.1-6.5 and in figure 6.2. 
6.4.: Discussion 
Unfortunately it was not possible to obtain an age-matched control population for this 
survey. However, the phenomena observed do not appear to be significantly age-dependent. 
The diabetics, both NIDDM and IDDM, show significantly reduced responses to PGE 1 at the 
concentrations studied. These observations are in agreement with results in the literature, 
showing decreased sensitivity to the physiological analogue of PGE 1, prostacyclin, in 
diabetics45. Prostacyclin and PGE1 are known to share a common receptor112, but their lack 
of effect on diabetic platelets does not appear to be mediated via altered PGI2/PGE 1 
receptors. This suggests a fault in either the coupling of the receptor to adenylate cyclase, a 
fault in the adenylate cyclase itself, or an increased platelet phosphodiesterase activity, all of 
which would lead to a lower cAMP level and hence a greater tendency towards aggregation 
in diabetics. 
A second condition in which decreýscd platelet prostacylin sensitivity has been 
reported is Behcet's Syndrome113, a vasculitic disorder in which thrombosis of both arteries 
and veins occurs. 
Only the IDDM patients show a noticable increase in response to ADP (iOD1) 
(p>0.1), but this is only just significant. Previous studies have reported increased platelet 
response to ADP in diabetes, but an equal proportion of researchers claim little or no 
difference compared to age-matched controls45. The inconsistency of these reports may be 
due to variations in the quality of diabetic control of the patients and to different drug 
therapy, particularly where drugs known to modify platelet function are concerned. In addition 
to common anti-aggregatory, but non-diabetes specific drugs such as aspirin21 and calcium- 
antagonists78-83, certain anti-diabetic drugs such as metformin are known to modify platelet 
114 function 
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VARIABLE CONTROLS IDDM NIDDM 
Age 35.45+/- 45.00+/- 60.90+/- 
14.07 16.56 8.81 
N. S. P>0.001 
QOD1 0.323+/- 0.449+/- 0.368+/- 
0.102 0.158 0.118 
p>0.1 N. S. 
% Inhibition by 54.92+/- 30.41+/- 22.91 +/- 
30nM PGE 1 16.11 18.19 15.02 
p>0.005 p>0.001 
% Inhibition by 79.28+/- 60.67+/- 56.69 +/- 
6OnM PGEI 16.27 18.75 19.45 
p>0.025 p>0.01 
"Recovery": 30nM -2.42+/- -15.11 +/- 24.25 +/- PGE1 (10nM Insulin) 13.88 61.39 45.91 
N. S. N. S. 
"Recovery": 30nM 4.04+/- 24.78+/- 67.55 +/- 
M Insulin) PGE1 (l 22.10 43.59 58.31 ,. 
P>0.01 p>0.1 
"Recovery": 6OnM -1.32+/- 15.60+/- 10.30 +/- 
PGE1 (10nM Insulin) 6.69 29.10 22.52 
N. S. N. S. 
"Recovery": 6OnM 5.84+/- 16.40+/- 26.42 +/- 
PGE1 (11 M Insulin) 8.23 35.03 25.14 
N. S. p>0.05 
Table 6.4. Quantitative Summary of Results. 
POSITIVE INSULIN EFFECT POSSIBLE EFFECT NO EFFECT 
CONTROLS 3 2 7 
IDDM 5 3 3 
NIDDM 9 3 1 
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Chapter 7 
SPONTANEOUS PLATELET AGGREGATION IN WHOLE BLOOD 
125 
7.1 : Background 
When investigating spontaneous or abnormal platelet aggregation, pa-icularly in vivo, 
it is important not to forget the role played by the other cellular constituents of the blood. 
Preparation of PRP both increases the concentration of plati is relative to whole blood, and 
removes almost all the erythrocytes and white cells. 
In addition to the documented platelet abnormalities seen in diabetes 
mellitus38,39,45, there have been numerous reports of atypical red121 and white 
corpuscle 116-120 properties and behaviour, some of which may have important haemostatic 
consequences in diabetes. 
On stimulation by an appropriate agent, human neutrophils undergo the "respiratory 
burst". This consists of a massive increase in oxygen consumption by the cells, resulting in 
the production of a range of partially reduced "active" oxygen species, implicated in bacterial 
killing; singlet oxygen (1A 02), peroxide radical (HO. 2), hydroxyl radical (OH-) and 
superoxide anion (02-') 122. In addition to their bactericidal activity, these substances are 
potentially responsible for tissue damage, such as induction of vascular permeability, 
destruction of endothelial cells, enzyme inactivation and platelet activation 
122. 
The effect of OH- on platelets has been well studied by Violi et all 
23. Platelets 
produce free radicals as by-products of the cyclo-oxygenase pathway and OH- scavengers 
significantly inhibit platelet aggregation, suggesting a self-activating role for free radicals 
produced by platelets. Hence, bacterial infection and neutrophil activation may play a part in 
platelet aggregation in vivo. 
During the respiratory burst, neutrophils emit light, a phenomenon known as 
chemiluminescence. By measuring this light emission using a scintillation counter, Littarru's 
group' 18,119 were able to show that neutrophils from diabetic patients gave a higher 
"resting" or unstimulated chemiluminescence and a lower stimulated response than non- 
diabetic controls. This behaviour was more evident in diabetics with recurrent infections. The 
persistant basal chemiluminescence of diabetic neutrophils suggests that they are 
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permanantly "poised" or partially activated in vivo, a condition possibly analagous with the 
"hypersensitive" platelets seen in the condition, resulting in a small but potentially important 
increase in circulating free radicals and the ensuing likelihood of tissue damage. 
Other reported neutrophil abnormalities in diabetes include defective chemotaxis, 
adherence117 and phagocytosis120. However , Valerius et al 
116 have reported that there is 
no difference in chemotaxis of neutrophils between diabetics and controls. Similar 
inconsistences have been reported for other factors of the neutrophils bactericidal 
mechanism. 
In addition to blockages caused by platelet aggregates, both red and white cells may 
occlude small blood vessels. Normally, the fluidity of erythrocyte and leukocyte membranes 
allows them sufficient deformability to pass through capillaries of smaller diameter than the 
cells themselves. A reduction in erythrocyte deformability has long been recognised as a 
side-effect of diabetes mellitus45,121 and Vermes et al 120 have recently shown that 
leukocytes from diabetics show a decreased deformability similar to that seen in diabetic red 
cells. This phenomenon correlated well with diabetic microvascular disease. 
Erythrocyte deformability appears to be directly linked to insulin concentrations since 
the abnormal deformability in IDDM can be rapidly reversed by good diabetic control 
achieved with an artificial pancreas 120. Even when hyperglycaemia was maintained, insulin 
infusion was able to increase red cell deformability, indicating that low insulin, rather than 
high glucose is to blame for the abnormality 120. However, it is unlikely that insulin will have 
much effect on the decreased erythrocyte deformability seen in NIDDM because these 
patients possess significantly fewer red cell insulin receptors than healthy controls 
1 04. In 
addition, diabetics have been shown to possess a defective erythrocyte membrane Na+/K+- 
ATPase with a significantly increased activity124. This activity is returned to normal by 
insulin therapy. 
The potential role of erythrocytes in haemostasis and spontaneous platelet aggregation 
(SPA) has long been recognised. As long ago as 1961, Gaarder et all 
I identified ADP from 
erythrocytes as an important trigger for platelet activation. Much more recently, Goldsmith et 
a/125,126 have shown that SPA can occur in whole blood in the absence of red cell lysis or 
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platelet granule release. The activating factor was found to be ADP, suggesting a sublytic 
release from the erythrocytes themselves. 
A number of observations at autopsy have suggested that platelet aggregates form in 
vivo and may have a patholgical role in sudden death in man4. In addition, small platelet 
aggregates may block smaller blood vessels such as retinal capilliaries, a factor believed to 
play a major role in the development of diabetic microangiopathy. Wu and Hoak 127 were the 
first to describe a method for quantifying platelet aggregates ex vivo. There have however, 
been frequent criticisms of the Wu and Hoak method ranging from artifactual formation of 
red cell debris, counted mistakenly by elctronic counters as platelets, to loss of certain 
platelet subpopulations by centrifugation during preparation of samples. Modified versions of 
the Wu and Hoak technique have described "circulating" platelet aggregates in a variety of 
clinical conditions including myocardial infarction, stroke, deep vein thrombosis, sickle cell 
anaemia and diabetes mellitus, but doubts still exist as to whether or not the aggregates 
actually exist in vivo, or are fomed during venupuncture 131 
If the latter is the case, then the presence of aggregates is more likely to represent the 
existence of "hypersensitive" or pre-activated platelets, which aggregate spontaneously and 
rapidly ex vivo. 
Erythrocytes may have a second role to play in haemostasis. In addition to platelet 
aggregates, platelets have frequently been seen in aggregates with erythrocytes (see figure 
7.1). The attatchment of platelets to erythrocytes could lead to drastic changes in the 
deformability of the red cell, causing occlusion of small blood vessels. 
128 In vitro SPA occurs to a much greater extent in whole blood than in PRP-130 
Saniabadi et all30 have shown that increasing the number of red cells present in relation to 
PRP increases the degree of SPA seen. In addition, this SPA can be partially inhibited by the 
presence of the ADP-destroying enzyme, apyrase 129 strongly implicating a red cell/platelet 
interaction and ADP release as important steps leading to SPA. 
The following experiments seek to characterise SPA in whole blood in healthy 
controls and three classes of patients at risk of thrombotic episodes; diabetics, psoriasis 
sufferers 132, and people at risk of thrombosis taking the anticoagulant drug Warfarin 133. 
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7.2.1.: General Method 
Whole blood samples were obtained from informed donors by venepuncture. Unless 
otherwise stated, all samples were collected into 3.8% citrate anticoagulant (final 
concentration 0.38%). 
1.0 to 1.5m1 aliquots of blood were removed, placed in siliconised, capped 
aggregometry cuvettes (LIP ltd. ) and agitated by rolling or gentle stirring at 22 or 37°C. 
At regular intervals, the platelet numbers were measured by passing 1O($ of each 
sample through the Technicon H* 1 or Technicon H* I Jr. whole blood haematological 
analysers at the Coventry and Warwickshire hospital. 
The maximum degree of SPA is measured as the lowest number of "free" platelets 
seen during the experiment, and expressed as a percentage of the initial or highest number of 
free platelets seen during a paticular experiment. 
7.2.2.: The Technicon H* 1 Whole Blood Analyser 
The H* 1 counts red cells, white cells and platelets by sophisticated laser light- 
scattering techniques. The H*1 Jr., most frequently used during the following experiments 
lacks the H* 1's ability to differentiate between the different types of white cells 133,134 
The performance characteristics of the H* 1, from Technicon's own technical 
specifications, are given in table 7.1. 
In addition to counts of the diferent types of blood cells, the H* I provides histograms 
of red cell volume, haemoglobin concentration, and platelet volume. 
The platelet counting method gives linearity from l Ox 109/1 to 700x 109/1. 
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PARAMETER LEVEL WITHIN-RUN STANDARD WITHIN-RUN STANDARD 
(units) (mean) DEVIATION DEVIATION, 95%C. I. * 
Red Cells 4.31 0.041 0.05 
(x1012/1) 
Platelets 97 3.7 4.5 
(x 109/1) 
Platelets 338 7.0 8.6 
(x 109/1) 
White cells 7.59 0.14 0.17 
(x 109/1) 
*, 95% Confidence Interval; The s. d. has a 95% probability of being smaller than this value. 
Table 7.1.: Technicon H*1 specifications 
3.8% trisodium citrate solution: Used in the ratio of lml to 9m1 blood to give 0.38% 
citrated whole blood. 
Sterile vacutainers (B. D. ltd. ) 4.5m1 volume: 
(i) Citrate 
(ii) Lithium Heparin 
(iii) EDTA 
Prostaglandin El solution: 15µM stock, diluted to l50nM in blood, prepared fresh 
each day. 
Adenosine diphosphate solution (Sigma): Special platelet aggregation reagent, 
reconstituted with water to give a buffered 0.2mM ADP solution. 
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Apyrase, grade V from potato (Sigma): 200 units/ml stock suspension. 
Pyruvate kinase, type III (Sigma): 1000 units/ml stock suspension. 
Phospho(enol)pyruvate, mono(cyclohexylammonium) salt (Sigma): 10mM stock 
solution, prepared fresh each day. 
Insulin, from bovine pancreas (Sigma): 150 i. u. /ml stock suspension, prepared fresh 
each day. 
Lipopolysaccharide, from Escherichia coli, serotype 0111: B4 (Sigma): 0.5mg/ml 
stock solution. 
Red blood cells, human : 4% RBC suspended in phosphate-buffered saline (Sigma); 
(i) Group "0", glutraldehyde treated, 
(ii) Group "0", trypsin and gluteraldehyde treated, 
(iii) Group "0", neuraminidase and gluteraldehyde treated. 
D-glucose (Fisons): 3.5M stock solution. 
D-galactose (Sigma): 1. OM stock solution. 
N-acetyl-glucosamine: L OM stock solution. 
7.2.4.: Reconstitution of "treated" red blood cell samples. 
12.5m1 of the 4% RBC suspension was centrifuged at 200g for 5 minutes to give 
approximately 0.4m1 of "packed" red cells. The supernatant was removed and the pellet 
resuspended in 0.6m1 of PRP from the appropriate donor. 
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7.3.: Results 
71x eriment 7.1 " The temperature dependence of SPA in whole blood. 
Citrated blood samples were obtained from three donors, AJS, RJB and BEPS, and 
aliquots of each were mixed at 22 and 37°C to establish the differences 
in SPA at each 
temperature. 
These results are expressed graphically in figure 7.2. 
The degree of SPA in each sample was as follows; 
AJS; SPAm (22)= 13.9% SPAmax(37)= 37.7% 
WB; SPAm j(22)=11.8% 
SPAmax(37)= 58.3% 
BEPS; SPAm (22)= 17.6% SPAm (37)= 49.5% 
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FIGURE 2" A comparison of whole blood SPA at 
2211 and 37°C in 3 healthy controls. 
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Clearly, whole blood SPA occurs to a greater degree at physiological temperature 
rather than room temperature. In addition to the possiblity of enhanced sub-lytic release of 
ADP from red cells, the platelet's own metabolism will be most effective at 37°C. Hence, 
stimulated platelets will form and release secondary agonists more rapidly. 
7.3-2.1 .: A comparison of Citrate and Heparin anticoagulants. 
Two blood samples were collected from the same donor, BEPS. One was collected 
into a standard citrate containing tube, the other into a heparinised tube. Aliquots of each 
were stirred at 37°C for 3 hours and H*1 counts were taken regularly. 
ANTICOAGULANT TIME SINCE VENUPUNCTURE (minutes) 
30 50 70 110 175 
Citrate 177 153 84 64 70 
Heparin 152 103 53 55 64 
All platelet numbers x 109/1. 
Citrate: SPAmax= 63.8% 
Heparin: SPAmax= 65.1% 
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Hence, there appears to be little difference in the degree of SPA observed using these 
two anticoagulants. Possibly the heparin-treated sample shows a faster SPA than citrated 
blood. 
X2.2.; A comparison of citrate and EDTA anticoagulants. 
(a) Blood samples were collected from donors AJS and BEPS (twice) into standard 
vials containing anticoagulants EDTA, citrate, or citrate plus added l 50nM PGE 1. Each 
sample was split two ways and either rolled at 22°C or stirred at 37°C. Platelet counts were 
compared before and after 30 minutes of mixing. 
Donor and date. 
SAMPLE BEPS, 31.10.88 AJS, 31.10.88 BEPS, 1.11.88 
20min. 50min. 20min. 50min. 20min. 50min. 
EDTA stirred 223 226 145 176 221 248 
EDTA rolled 218 200 148 150 215 198 
Cit. stirred 58 149 150 140 193 160 
Cit. rolled 47 132 147 142 196 165 
Cit. stirred 
+PGE1 
198 287 153 148 234 228 
Cit. rolled 
+PGE1 
153 247 150 142 220 221 
All Platelet counts x109/1 
Table 7.4.: The effect of EDTA and PGE1 on SPA. Platelet numbers x10911 
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(b) Blood samples from donor AJS were collected into standard EDTA or citrate + 
PGE1 (150nM) vials and aliquots were stirred at 37°C to investigate the difference between 
EDTA and POE 1-dependent spontaneous platelet disaggregation. 
TIME(minutes) CITRATE + PGE1 EDTA 
15 154 163 
30 165 156 
45 163 154 
105 169 171 
170 162 196 
All Platelet counts x109/1 
Table 7.5.: Time denendance of PGE1 and EDTA-induced spontaneous platelet 
disaggregation: Platelet numbers x 109/ 1. 
See also figure 7.3. 
The three types of anticoagulant investigated work by different methods. Heparin, a 
negatively-charged polysaccharide, enhances the inhibitory action of antithrombin III, which 
inactivates thrombin by forming an irreversible complex with it3. In contrast, both citrate and 
EDTA work by binding calcium ions. Calcium (or coagulation factor IV) is involved at 
several sites in both the intrinsic and extrinsic pathways of coagulation. In addition, several 
stages of platelet activation and aggregation are Cat+-dependent (see section 1.4. ). 
It is clear from the results shown here that citrate and EDTA have very different 
effects on SPA. Whereas citrate, like heparin, allows SPA to occur, apparently unhindered, 
EDTA severely inhibits SPA or, under the right conditions, causes a spontaneous 
disaggregation of platelet aggregates. 
AJS, 31.10.88. BSS. 1.11.88. BFYS, 31.10.88. 
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Experiment 7.3.2.2(b) suggests that the capacity of EDTA to dissociate agregates is 
even greater, in the long term, than PGEl. 
EDTA inhibits platelet aggregation by tightly chelating all the plasma Ca2+ essential 
for formation of the GPIIb/GPIIIa complex, the fibrinogen receptor. Hence, platelet 
aggregation in EDTA-anticoagulated blood will not pass the "shape-change" phase. Although 
citrate also binds Ca2+, it does so very weakly in comparison to EDTA. Hence, Ca2+ is 
easily removed from the citrate complex by platelets and can be used for formation of the 
fibrinogen receptor. In contrast, EDTA is a powerful enough chelator of Ca2+ to remove it 
from the GPIIb/GPIIIa complex, even when fibrinogen is bound. Hence, EDTA is able to 
dissociate small platelet aggregates. 
The results of experiment 7.3.2.2(a) are somewhat anomalous. Despite the two 
samples from BEPS being collected on consecutive days, great differences in platelet 
behaviour are seen. On the first day, a tremendous degree of SPA had occured even before 
mixing commenced. These aggregates were obviously very transient since gentle mixing, 
even in the absence of PGE1 or EDTA caused a massive disaggregation. On the second day, 
blood taken from the donor's other arm behaved perfectly normally, very much as the sample 
from donor AJS had the previous day. 
It was deduced that the poor quality of the earlier platelets from donor BEPS was due 
to defective phlebotomy, possibly a collapsed vein. 
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73-3.1; A longtitudinal study to determine individual variations in SPA. 
Citrated whole blood was obtained from donors AJS and BEPS on numerous 
occasions over an eight month period. The degree of SPA was ascertained after mixing at 
either 22 or 37°C. 
Donor AJS ; age 23/24. 
DATE EXPERIMENTAL 
TEMPERATURE 
INITIAL PLATELET 
COUNT (x109/1) 
%SPA TIME FOR 
MAXIMUM SPA 
(minutes) 
29.09.88 370 142 15.5 165 
07.10.88 370 112 22.3 45 
14.10.88 37° 157 37.6 90 
07.11.88 37° 151 37.1 180 
22.11.88 37° 168 28.6 120 
11.01.89 37° 171 32.2 100 
05.05.89 37° 138 31.1 120 
31.10.88 22° 147 3.4 90 
07.11.88 22° 165 13.9 180 
28.04.89 22° 153 9.1 50 
21.06.89 22° 158 8.9 90 
Donor BEPS ; age 50/51 
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DATE EXPERIMENTAL 
TEMPERATURE 
INITIAL PLATELET 
COUNT (x109/1) 
%SPA TIME FOR 
MAXIMUM SPA 
(minutes) 
26.09.88 37° 164 20.1 180 
03.10.88 37° 142 20.4 180 
18.10.88 37° 202 27.7 160 
18.11.88 37° 177 63.8 110 
24.11.88 37° 216 48.6 195 
01.12.88 37° 224 57.7 200 
17.04.89 37° 173 52.6 100 
24.04.89 37° 112 66.5 120 
22.05.89 37° 164 28.0 120 
31.10.88 22° 47 .. * 0 
01.11.88 22° 196 15.8 50 
24.11.88 22° 215 11.8 135 
01.12.88 22° 222 35.5 120 
06.12.88 22° 209 21.5 180 
24.04.89 22° 186 39.2 120 
09.05.89 22° 186 28.0 120 
09.06.89 22° 208 37.5 110 
* see section 7.3.2.3. 
Table 7.7. SPA. individual variation in donor BEPS 
These results are expressed graphically in figure 7.4. 
FIGURE 7.4: Long-term variations of SPA and 
initial platelet count in two 
healthy controls. 
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Figure 7.4 shows the variations in platelet number and SPA of the two control donors. 
Clearly there are large fluctuations in both SPA and platelet number. Platelet concentrations 
are kept relatively constant in vivo by the hormone thrombopoietin, which stimulates the 
formation of new platelets from megakaryocytes when needed3'4. Many of the fluctuations 
are undoubtedly due to the presence of some platelets as microaggregates (see section 
7.3.4.1. ). 
SPA at 37°C is consistently higher than at 22°C as expected, and is paticularly 
consistent in donor AJS. Donor BEPS shows rather more variability in both platelet number 
and degree of SPA. 
The mean values for platelet number and SPA are as follows; 
AATS Platelet number = 151.1 +/- 16.6 x 109/1 (n=11) 
SPA, 37°C = 8.8 +/- 4.3 % (n=4) 
SPA, 22°C = 29.2 +/- 8.0 % (n=7) 
BFM Platelet number = 192.3 +/- 24.5 x109/1 (n=16) 
SPA, 37°C = 27.0 +/-10.9 % (n=7) 
SPA, 22°C = 42.8 +/- 18.8 % (n=9) 
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Method as for section 7.3.3.1. 
PATIENT AGE TYPE INITIAL 
PLATELET 
COUNT (x109/1) 
EXPERIMENTAL 
TEMPERATURE 
9%SPA ME FOR 
MAX. SPA 
(minutes) 
H3 71 N+ 162 37° 39.5 165 
H4 46 I+++ 221 37° 3.2 160 
H5 46 1+ 308 37° 38.0 175 
H6 61 I++ 146 37° 34.9 105 
H7 78 N+ 163 370 .0 170 H8 71 N+ 224 370 8.3 75 
H11 56 I+++ 379 37° 30.6 180 
H12 40 1+ 186 37° 41.4 60 
A14 35 I+++ 546 37° 14.3 80 
RI 64 N- 192 371 41.0 130 
H5 46 I+ 262 22° 8.0 175 
H6 61 I++ 198 22° 10.6 105 
H8 71 N+ 201 22° 42.7 75 
H11 * 56 I+++ 371 22° 10.2 180 
RI 64 N- 207 22° 28.0 45 
il 80 I++ 198 22° 23.7 120 
J2 63 1+ 251 22° 32.7 115 
* J3* 57 1+ 329 22° 37.1 120 
J4 72 1+ 180 22° 36.7 120 
J6 46 I++ 168 22° 23.8 90 
* J7'` 70 N++ 291 22° 21.6 80 
J8 30 I++ 162 22° 23.4 90 
Key: N= NIDDM, I= IDDM, -= no complications, 
+= background retinopathy, ++ = severe retinopathy, 
+++ = retinopathy plus proteinuria. 
*= on adalat. 
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Method as for section 7.3.3.1. 
PATIENT AGE CONDITION INITIAL 
PLATELET 
COUNT 
(x 109/1) 
EXPERIMENT 
TEMPERATURE 
%SPA TIME FOR 
MAX. SPA 
(mins. ) 
HQ 60 F. E. 306 370 34.0 165 
VT 74 DVT, F. E. 218 370 34.4 45 
LO 32 P. E. 365 22° 37.8 90 
JS 72 P. E. 190 22° 75.3 90 
AMF 24 P. E. 220 22° 38.2 180 
im 59 P. E. 309 22° 28.5 130 
HQ 60 F. E. 306 22° 16.0 165 
JC 56 DVT 341 22° 53.1 90 
Key : F. E. = Femoral embolism 
P. E. = Pulmonary embolism 
DVT= Deep vein thrombosis 
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Method as section 7.3.3.1. 
PATIENT AGE DEGREE OF INITIAL EXPERIMENTAL %SPA TIME FOR 
PSORIASIS PLATELET TEMPERATURE MAX. SPA 
COUNT (mins. ) 
(x 109/1) 
DLS 60 Mild 187 22° 5.9 60 
BW 64 Mild 204 22° 22.0 135 
CP 38 Severe 270 22° 33.0 105 
WW 58 Severe 277 22° 30.7 75 
Table 7.10.: Whole blood SPA in psoriasis patients. 
All three groups of patients investigated have previously been reported to show 
enhanced platelet activation both in vivo and in vitro45,132,133. Considerable differences 
between individuals exists in both platelet number and SPA. Owing to the infrequency of 
patient's visits to out-patient clinics, it was not possible to study any of the patients on more 
than one occassion and so it was not possible to establish whether, for example, diabetic H8 
consistently shows over 60% SPA, or if there were any increases in SPA with progression of 
vascular disease. 
The mean results for each group of patients were as follows; 
Diabetics Age = 58.0 +/- 15.2 years (n=17) 
Platelet no. = 242.9 +/- 95.9 x 109/l (n=22) 
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SPAm (22) = 24.9 +/- 11.3 % (n=12) 
SPAm (37) = 35.7 +/- 17.6 % (n=10) 
Warfarin Age = 53.9 +/- 19.0 years (n=7) 
Platelet no. = 281.5 +/- 63.8 x109/1 (n=8) 
SPAmax(22) = 41.5 +/- 20.6 % (n=6) 
SPAmax(37) = 34.2 +/- 0.2 % (n=2) 
Psoriasis Age = 55.0 +/- 11.6 years (n=4) 
Platelet no. = 234.5 +/- 45.6 x 109/1(n=4) 
SPAm (22) = 22.9 +/- 12.3 % (n=4) 
The equivalent results from multiple assays of two healthy controls are given in 
section 7.3.3.1. 
147 
7.3.4.: The effects of PGE1 on whole blood SPA. 
7.34 1. A longtitudinal study to determine variations in platelet microaggregates. 
Citrated whole blood samples were obtained from donors AJS and BEPS on 
numerous occasions over a two month period. The degree of platelet disaggregation in the 
presence of l50nM PGEI was established and the number of platelets present as 
microaggregates expressed as; 
Maximum Platelet no. 
Donor BEPS; age 50. 
DATE EXPERIMENT INITIAL MAXIMUM %MICRO- TIME FOR 
TEMPERATURE PLATELET PLATELET AGGREGATES MAXIMUM 
OUNT COUNT DISAGG- 
x109/1) (x109/1) REGATION 
(minutes) 
26.09. 370 152 191 20.4 180 
03.10. 370 142 183 22.4 15 
18.10. 37° 199 205 3.0 160 
01.11. 37° 196 234 16.2 15 
01.11. 22° 96 221 11.3 50 
Table 7.11. ; Microaggregates. individual variations in donor BEPS. 
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Donor AJS ; age 23. 
DATE EXPERIMENTAL INITIAL MAXIMUM %MICRO- TIME FOR 
TEMPERATURE PLATELET PLATELET AGGREGATES MAXIMUM 
COUNT COUNT DISAGG- 
x109/I) ( x100/ 1) REGATION 
(minutes) 
31.09. 370 142 146 2.7 15 
07.10. 371 106 142 25.3 45 
14.10. 370 157 174 9.8 45 
31.10. 370 147 153 3.9 15 
14.11. 37° 154 169 8.9 105 
31.10. 22° 147 150 2.0 15 
Table 7.12.. Microaggrggates. individual variations in donor AJS. 
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73-4 Microaggregates in diabetic patients. 
Method as for section 7.3.4.1. 
Ressul-ts 
PATIENT AGE DEGREE OF 
ICRO- 
GIOPATH 
XPT. 
MP. 
INITIAL 
PLATELET 
COUNT 
(x109/1) 
MAXIMUM 
PLATELET 
COUNT 
(x109/1) 
%MICRO- 
AGGREGATES 
H3 71 37° 162 253 36.0 
H4 46 ++ 37° 221 221 0 
H5 46 370 308 308 0 
H6 61 + 37° 146 257 43.2 
H7 78 37° 162 185 12.4 
H10* 71 + 37° 342 342 0 
H11 * 56 ++ 37° 398 420 5.2 
H6 61 ++ 22° 198 239 17.1 
H7 78 22° 162 165 1.8 
*= Patients taking Adalat 
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7.3.4,1,. 
-Microaggregates 
in patients at risk of thrombosis (taking Warfarin). 
Method as in section 7.3.4.1. 
PATIENT AGE EXPT. INITIAL MAXIMUM %MICRO- 
TEMP. PLATELET PLATELET AGGREGATES 
COUNT COUNT 
(x109/1) (x109/1) 
LO 32 370 365 384 4.9 
JS 72 370 190 211 11.0 
AMF 24 37° 220 239 7.9 
JM 59 37° 308 308 0 
7.3.4.4.: Discussion. 
Platelet microaggregates, formed either in vivo, or during venupuncture, will not be counted 
by the Technicon H* 1. However, their presence may be an important indicator towards the 
possibility of thrombotic episodes. 
Splawinska et all38,139 have previously reported that prostacyclin was able to 
increase platelet numbers in whole blood. The experiments reported here employed the 
cheaper, more stable analogue, PGE1 to dissociate aggregates. Mean results at 22° and 370 
were as follows; 
Control AJS: Age = 23 
% Microaggregates(22) = 2.0 (n=1) 
% Microaggregates(37) =10.1 +/- 9.0 (n=5) 
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Control BEPS: Age = 50 
" Microaggregates(22) = 11.3 (n=1) 
" Microaggregates(37) = 15.5 +/- 8.7 (n=4) 
Di s: Age = 61.3 +/- 12.7 (n=7) 
" Microaggregates(22) = 9.45 +/- 10.8 (n=2) 
% Microaggregates(37) = 13.8 +/-18.3 (n=7) 
Warfarin: Age = 46.8 +/- 22.5 (n=4) 
% Microaggregates(37) = 5.95 +/- 4.7 (n=4) 
The results appear to show little difference between the different groups of donors. 
However, the occurence of PGE1-insensitive microaggregates must be considered. These 
microaggregates, possibly formed by ADP-independent SPA (see section 7.3.6), may be 
increased in number in the various pre-thrombotic states. Experiment 7.3.2. demonstrated 
that PGE1 lacks the ability to dissociate all microaggregates since EDTA was more effective. 
Hence, a more complete study might include the time-dependent increase of platelet number 
in EDTA-anticoagulated blood. 
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Citrated whole blood was obtained from donor GMW. Samples were mixed at 22°C 
in the presence of increasing doses of LPS (0,50,500,5000 ng/ml). 
TIME LIPOPOLYSACCHARIDE CONCENTRATION 
(mins. ) 0 50ng/ml 500ng/ml 5000ng/ml 
15 185 156 161 164 
55 167 143 124 133 
80 152 158 127 130 
The degree of SPA in each sample was as follows; 
Ong/ml LPS = 17.8% 
50ng/ml LPS = 22.7% 
500ng/ml LPS = 33.0% 
5000ng/mI LPS = 29.7% 
(assuming initial platelet count to be 185 in all samples) 
Platelet 
Counts 
(x 109/1) 
Gram-negative bacteria produce an endotoxin that is a lipopolysaccharide (LPS) 
composed of three principal regions; the O-polysaccharide, the R-core oligosaccharide, and 
the lipid, A. The structure of the main toxic component, lipid A, is highly conserved among 
Gram-negative bacteria. In contrast, the O-side chains are highly diverse and also highly 
mutable, enabling the bacteria to stay one step ahead of the host's defense systems6. 
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Sepsis due to Gram-negative bacteria is often complicated by disseminated 
intravascular coagulation and thrombocytopenia. Csako et a192 have reported that purified 
endotoxin is able to cause a slowly developing platelet aggregation in citrated whole blood in 
vitro, but not in PRP, suggesting an indirect activation of platelets by endotoxin. This type of 
SPA is similar to the "non ADP-dependent" SPA described in section 7.3.6. 
The paticular LPS employed in this experiment, from E. coli serotype 0111: B4, has 
been shown to initiate aggregation of platelets in plasma via the generation of thrombin at the 
surface of monocytes92. However, Davis and Johnstone92 reported that E. coli 0111 LPS 
actually blocks aggregation in whole blood. 0111 LPS in this survey causes up to 15.2% 
additional SPA compared to untreated whole blood. This result may indicate that 
susceptibility to endotoxin varies from individual to individual. However, there seems little 
doubt that bacterial endotoxins can cause platelet activation in vitro. If these events are 
repeated in vivo, then bacterial infection might be expected to increase circulating 
microaggregates. 
In view of the increased susceptibility of diabetic patients to infections, it is possible 
that the infectious agent itself could play an important role in the development of diabetic 
microangiopathies. 
154 
7.3.6.: Experiment: Is P responsible for whole blood SPA? 
7.3.6.1. The effect of potato apyrase on whole blood SPA. 
(a) Two citrated blood samples were obtained from donor AJS. One sample was 
untreated. To the other was added apyrase to a final concentration of 0.27mg/ml blood. Both 
samples were stirred at 37°C. 
TIME PLATELET COUNT (x109/1) 
(minutes) -Apyrase +Apyrase 
15 165 174 
30 168 155 
45 160 151 
60 157 158 
90 143 150 
120 120 143 
180 120 143 
These results are expressed graphically in figure 7.5. 
% SPA in absence of apyrase = 28.6% 
% SPA in presence of apyrase = 17.8% 
(b) Citrated blood samples were obtained from donpor BEPS on three occassions over 
a period of two weeks and the relative effect of apyrase at 3700 and 22°C was established. 
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(i)37°C 
TIME PLATELET COUNT (x 109/1) 
(mies. ) -A. (24.11.88) -A. (1.12.88) +A. (1.12.88) +A. (6.12.88) 
10-15 216 224 222 227 
20-30 214 170 188 202 
45-50 196 171 185 189 
70-80 181 155 168 173 
95 174 - - - 
120 - 113 130 163 
135-140 150 92 113 - 
180-195 109 94 116 164 
Table 7.17.: Donor BEPS: Apyrase and SPA at 372 
Key: -A = Apyrase absent 
+A = Apyrase present 
% SPA in absence of apyrase (i) Date, 24.11. = 49.5% 
(ii) Date, 01.12. = 58.9% 
% SPA in presence of apyrase (i) Date, 01.12. = 47.7% 
(ii) Date, 06.12. = 27.7% 
157 
(ii)22°C 
TIME PLATELET COUNT (x109/1) 
(mies. ) -A. (24.11.88) -A(1.12.88) -A(6.12.88) +A(6.12.88) 
10-15 215 222 209 212 
20-30 227 197 180 204 
45-50 208 175 195 193 
70-80 199 147 181 180 
95 189 - - - 
120 - 145 174 169 
135-140 187 145 - - 
180-195 192 143 164 168 
Table 7.18.: Donor BEPS: Apyrase and SPA at 22 
% SPA in absence of apyrase (i) Date, 24.1 1. = 13.0% 
(ii) Date, 01.12. = 21.5% 
(iii) Date, 06.12. = 35.6% 
% SPA in presence of apyrase , Date, 06.12. =20.7% 
See also figure 7.6. 
Potato apyrase has an ATPase activity as well as an ADPase activity. It catalyses the 
reaction; 
ATP ----- ' ADP + Pl ' AMP + 2P1 
Hence, any ATP or ADP released from platelets or erythrocytes will be rapidly 
converted to non-aggregatory AMP by the apyrase. 
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Figure 7.5 shows that apyrase is indeed capable of inhibiting SPA. In the absence of 
apyrase, a further 10.8% aggregation occurs. This may be termed "ADP-dependent SPA", 
whereas the 17.8% aggregation, in the presence of apyrase is presumably "ADP- 
independent SPA". Figure 7.6 shows the mean SPA in the presence and absence of apyrase 
at 371 and 22°C. These results, averaged out from three blood samples collected on different 
days appear to indicate very little inhibition of SPA by apyrase. However, the behaviour of 
the platelets varies from day to day. This is most clearly shown by a comparison of SPA in 
the absence of apyrase at 22°C on each day. 
A comparison of samples collected with or without apyrase on the same day indicates 
that inhibition of SPA is occuring, but not to a significant degree. At 37°(1.12.88), ADP- 
dependent SPA is 47.7% and ADP-independent SPA 11.2%. In contrast, the SPA at 
22°(6.12.88) appears to be almost entirely ADP-independent. 
The use of potato apyrase to destroy ADP presented some unexpected problems. The 
experiment of 6.12.88 showed a considerable, time-dependent agglutination of erythrocytes 
in the presence of apyrase at both 37° and 22°C (see figure 7.7). This behaviour was clearly 
due to some contamination of the apyrase itself. 
Matsumoto et a1140 have described and isolated a lectin from potato, solanum tuberosum 
agglutinin (STA) which recognises a specific sugar sequence, namely tri-(N-acetyl- 
glucosamine). The dimeric STA recognises this sequence and causes agglutination. "Pure" 
and "crude" STAs were purchased from Sigma and their ability to agglutinate a 2% 
suspension of erythrocytes (donor BEPS) was determined. 
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Results are shown below; 
1Oµg/ml +++ 
5 µg/ml ++ 
2.5 µg/ml + 
1.25 µg/ml + 
I µg/ml +/- 
0.1 µg/mi 
Crude Lectin 
- 
100 µg/ml ++ 
50 µg/ml + 
40 µg/ml + 
30 µg/ml +/- 
25 µg/ml +/- 
10 µg/ml - 
500 µg/ml ++ 
50 µg/ml ++ 
10 µg/ml + 
5 µg/ml + 
2.5 µg/ml +/- 
1 µg/ml - 
These results clearly show that potato apyrase is contaminated with STA to such a 
level that the agglutinating capacity of apyrase is actually greater than that of the "crude" 
commercial preparation. 
This contamination of apyrase could potentially pose problems for the study of SPA 
since the agglutinin could also recognise and bind platelet membrane glycoproteins, causing 
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an agglutination of platelets, as opposed to a true aggregation, masking apyrase's ADP- 
destroying effects. 
A second potential problem in the use of apyrase for preventing ADP-dependent SPA 
is that ATP acts as a substrate for the enzyme. Both platelets and erythrocytes contain 5 to 10 
times as much stored ATP as ADP. Any release of ADP will be accompanied by a 
concommitant release of ATP. This ATP will be rapidly converted to AMP, but there will be 
a transient ADP formation during this process which could activate platelets. 
For these reasons, a second ADP-destroying system was investigated. 
7.3-62.: The effects of Pyruvate kinase and Phospho(enol)pyruvate on whole blood 
SPA. 
(a) Citrated whole blood was obtained on two occassions, 7 days apart, from the same 
donor (AJS). Samples were mixed at either 220 or 37°C in the presence or absence of 20 
units/ml pyruvate kinase (PK) and 100µM phospho(enol)pyruvate (PEP). 
After two hours mixing, 5 or 10µ. M ADP was added to test the effectiveness of the 
ADP-destroying system. 
TIME 28.4.89(22°C) 5.5.89(37°C) 
(mies. ) -PK/PEP +PK/PEP +PK/PEP -PK/PEP +PKIPEP 
15 153 147 136 138 136 
35 145 159 152 100 137 
50-55 139 149 148 105 138 
80-85 149 148 150 96 140 
120 142 146 143 95 142 
ADP added 5µM 5µM 10µM 5µM 5µM 
130 7 144 
L133 ( 
39 
(124 
Table 7.19. The effect of PK/PEP on SPA: Donor AJS. 
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These results are expressed graphically in figure 7.8. 
% SPA -PK/PEP(22) `29-1% 
+PK/PEP(22) (i) = 2.7% 
+PK/PEP(22) (ii)= 5.9% 
-PK/PEP(37) = 31.1 % 
+PK/PEP(37) =0 
As expected, the 370 sample shows considerably more SPA than the 22° sample. 
Pyruvate kinase, which converts ADP to ATP; 
ADP + PEP pXEUvate kinase _ ATP + Pyruvate 
almost totally abolishes SPA. The effectiveness of the ADP-destroying system is 
shown by the lack of response to 5 or 10µM ADP in the samples treated with PK/PEP. These 
results indicate that the SPA seen in this donor's blood is almost totally of the ADP- 
dependent type. 
(b) Citrated whole blood was obtained from donor BEPS. Samples were mixed at 
either 22° or 37°C in the presence or absence of 20 units/ml PK and 100µM PEP. After two 
hours of mixing, 2µM ADP was added to test the effectiveness of the ADP-destroying 
system. 
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FIGURE 7.9: PK/PEP and SPA; donor BEPS 
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TIME PLATELET COUNT (x 109/1) 
(mies. ) -PK/PEP(22°) +PK/PEP(22°) -PK/PEP(37°) +PK/PEP(370) 
30 
60 
90 
120 
186 
172 
166 
113 
192 
195 
181 
149 
112 200 
115 172 
87 126 
67 84 j 
2µM ADP added to each sample. 
130 90 133 67 7711 
These results are expressed graphically in figure 7.9. 
% SPA -PK/PEP(22)= 43.5% 
+PK/PEP(22)= 25.5% 
-PK/PEP(37)= 66.5% 
+PK/PEP(37)= 58.0% 
The lower dose (2µM) of ADP employed to test the PK/PEP efficiency 
failed to cause 
any additional platelet aggregation in this experiment. Presumably, the 
2µM ADP is 
insufficient to cause irreversible aggregation in this donor. 
In contrast to the previous experiment, a major proportion of the 
SPA observed was 
ADP-dependent. The degree of ADP-independent SPA increased with temperature. 
The lack of response to 2µM ADP poses an interesting question. How much ADP 
needs to be released from erythrocytes or platelets to cause the ADP-dependent 
SPA? 
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7. . 3. The effects of PK and PEP on SPA in diabetic patients. 
Citrated blood samples were obtained from two diabetic patients. Samples were 
mixed at 220 or 370C in the presence or absence of PK and PEP. 
Patient Data 
Diabetic RI : Male, NIDDM, age 65, no microvascular complications. 
Diabetic J8 : Female, IDDM, age 30, retinopathy. 
TIME PLATELET COUNT (x 109/1) 
(mins) -PK/PEP(22°) +PK/PEP(22°) -PK/PEP(37°) +PKIPEP(37°) 
25 207 206 192 204 
40 156 199 158 188 
60 177 207 142 191 
90 170 209 162 180 
120 176 185 117 182 
135 167 180 110 176 
Table 7.21.: The effect of PK/PEP on SPA : Donor. diabetic R1. 
The sample from diabetic J8 was split into two, and PRP prepared from one half. The 
effect of PK/PEP on platelet aggregation in whole blood and PRP was then compared at 
22°C. 
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TIME PLATELET COUNT (x109/1) 
(mins. ) WHOLE BLOOD PRP 
-PK/PEP(22°) +PK/PEP(22°) -PK/PEP(37°) +PK/PEP(37°) 
10 166 168 262 261 
30 162 167 260 259 
55 147 162 244 271 
85 124 151 243 273 
110 149 148 238 268 
Table 7.22.: The effect of PK/PEP on SPA : Donor diabetic J8. 
These results are expressed graphically in figure 7.10. 
Discussion 
Patient RI shows fairly typical behaviour, the degree of SPA under each set of 
conditions being as follows; 
22°C : ADP-dependent SPA = 12.0% 
ADP-independent SPA = 12.6% 
37°C : ADP-dependent SPA = 29.0% 
ADP-independent SPA = 13.7% 
Thus, in this patient, only the ADP-dependent SPA increases at 37°C relative to 
22°C. 
The second patient, J8, shows similar behaviour at 22°C using whole blood; 
22°C WHOLE BLOOD: ADP-dependent SPA = 13.4% 
ADP-independent SPA = 11.9% 
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22°C PRP : ADP-dependent SPA = 9.2% 
ADP-independent SPA =0 
The equivalent PRP sample demonstrates that in the absence of erythrocytes, SPA is 
reduced, and in addition, is totally of the ADP-independent type. This strongly suggests that 
"ADP-dependent" SPA requires the presence of erythrocytes. 
7.3.6,4. Is Insulin involved in whole blood SPA in diabetic patients? 
Citrated blood samples were obtained from two diabetic donors. Samples were mixed 
at 22°C in the presence or absence of 20 units/ml PK, 100µM PEP and 1µM insulin. 
Diabetic JI: Female, IDDM, age 80, retinopathy. 
Diabetic J2; Female, IDDM, age 63, retinopathy. 
TIME PLATELET COUNT (x 109/1) 
(mins. ) -PK/PEP +PK/PEP -PK/PEP +PK/PEP 
+Insulin +Insulin 
20 198 221 183 198 
35 181 188 179 199 
60 159 186 159 195 
100 157 180 159 184 
120 151 164 158 184 
5µM ADP added to each sample 
130 10 111 13 109 
Table 7.23.: Whole blood SPA : Diabetic 11. 
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TIME PLATELET COUNT (x109/1) 
(mins. ) -PK/PEP +PK/PEP -PK/PEP +PK/PEP 
+Insulin +Insulin 
10 251 237 239 230 
30 228 236 248 250 
60 223 247 227 247 
75 214 244 232 241 
115 169 217 225 245 
5µM ADP added to each sample 
125 20 201 12 219 
Table 7.24.: Whole blood SPA : Diabetic J2. 
These results are expressed graphically in figure 7.11. 
Following the interesting effects of insulin on ADP-induced aggregation in PRP 
reported in chapter 6, it was decided to test the effects of high dose insulin on two IDDM 
patients. 
ii ADP-dependent SPA = 5.9% 
ADP-independent SPA =25.8% 
ADP-dependent SPA + insulin =11.8% 
ADP-independent SPA +insulin =16.7% 
J2 ADP-dependent SPA =20.5% 
ADP-independent SPA =12.1% 
ADP-dependent SPA + insulin = 5.7% 
ADP-independent SPA + insulin = 3.6% 
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Insulin has little effect on the total SPA seen in donor Ji, but clearly inhibits SPA 
from donor J2. 
7.3.6.5. The effects of PK/PEP on SPA in psoriasis patients. 
Citrated whole blood samples were obtained from two patients with severe psoriasis. 
Both samples were mixed at 2200 in the presence or absence of PK and PEP. 
Patient CP : Female, age 38. 
Patient WW : Male, age 57. 
TIME PLATELET COUNT (x 109/1) 
(mins. ) CP: -PK/PEP CP: +PK/PEP WW: -PK/PEP WW: +PK/PEP 
45 
75 
105 
135 
270 
216 
181 
220 
285 
197 
215 
224 
277 
192 
201 
193 
250 
234 
205 
173 
5µM ADP added to each sample 
145 7 205 42 147 
Table 7.25.: Whole blood SPA : Psoriasis patients. 
See also figure 7.12. 
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Interestingly the SPA of both patients is almost totally of the ADP-dependent type; 
CE ADP-dependent SPA = 2.1 % 
ADP-independent SPA =30.9% 
WW ADP-dependent SPA = 0.1% 
ADP-independent SPA =30.8% 
This behaviour is rather atypical. Berrettini et all32 reported enhanced spontaneous 
aggregation in PRP from psoriasis patients compared to controls. These results suggest that 
although the SPA in whole blood from psoriasis patients may not be greater in total than the 
general population's, the mecanisms underlying the development of the SPA are different. 
Both patients studied here would be expected to show similarly exaggerated SPA in PRP as 
Berrettini s patients did. 
7.3.6.6.: The effect of PK and PEP on SPA in two patients taking warfarin. 
Citrated blood samples were obtained from two non-diabetic patients taking the anti- 
thrombotic drug, warfarin. Samples were mixed at 22°C in the presence or absence of 
PK/PEP as before. 
Patient VT ; Female, age 74, femoral embolectomy (deep vein thrombosis). On 
warfarin for 10 months. 
Patient JC ; Female, age 56. 
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TIME PLATELET COUNT (x109/1) 
(mins. ) VT: -PK/PEP VT: +PK/PEP JC: -PK/PEP JC: +PK/PEP 
10 218 214 341 286 
30 183 209 - - 
45 150 223 239 257 
70 157 212 - - 
90 - - 160 233 
105 163 194 - - 
120 143 209 188 239 
5µM ADP added to each sample 
130 19 210 36 198 
Table 7.26.: Whole blood SPA : Patients at risk of thrombosis. 
See also figure 7.13. 
In contrast to the psoriasis patients, the potential thrombosis patients show both ADP- 
dependent and independent SPA; 
_YT_: 
ADP-dependent SPA = 21.4% 
ADP-independent SPA = 13.0% 
IC : ADP-dependent SPA = 34.6% 
ADP-independent SPA = 18.5% 
The degree of SPA is not extreme, considering the age of the donors. 
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Evidently, ADP plays a major role in the formation of platelet aggregates in whole 
blood. This observation is in agreement with Saniabadi's group 128-131 and others 125,126, 
who reported the effects of red blood cells and ADP-destroying systems on SPA. 
The inhibitory effects of two ADP-destroying systems on whole blood SPA and the 
varying degrees of ADP-dependent and ADP-independent SPA from numerous donors are 
reported here. The mechanisms of both types of SPA are still uncertain. ADP-dependent SPA 
appears to be dependent on the presence of erythrocytes. Recent work by a Canadian 
group125,126 has indicated that erythrocytes release ADP sub-lytically even when only 
gently agitated, and has shown that this ADP is able to activate platelets. 
The mechanism of ADP-independent SPA is rather more difficult to explain. Even in 
the presence of ADP-destroying systems capable of preventing aggregation induced by up to 
1Up M ADP, a considerable degree of aggregation can still take place. There are numerous 
candidates for inducing this form of SPA including thrombin, platelet-activating factor, 
immune complexes95, bacterial endotoxins92 or any combination of these. Alternatively, the 
non-ADP dependent SPA may be caused by platelets that are already pre-activated or 
"poised" to aggregate, either prior to venupuncture , or are activated 
by the process of 
venupuncture itself. 
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7.3.7. The effects of "Treated" erythrocytes on SPA in healthy controls and diabetics. 
Crbc = "control" red cells 
Nrbc = "neuraminidase" red cells 
Trbc = "trypsin" red cells 
Plt. no. = Platelet number x 109/1 blood 
RBC no. = Red cell number x 1012/1 blood 
7.3.7.1. Treated erythrocytes and SPA in a healthy control. 
Citrated blood was obtained from donor AJS. Whole blood and reconstituted samples 
(see 7.2.4) using each of the three types of fixed cells were rolled at 22°C. 
TIME VARIABLE DATE 21.6.89. 
(mies. ) Whole Blood PRP+Crbc PRP+Nrbc 
30 Plt. no. 
RBC no. 
158 
4.52 
119 
2.28 
190 
2.06 
60 Plt. no. 
RBC no. 
148 
4.48 
121 
2.37 
11 
1.99 
90 Plt. no. 
RBC no. 
144 
4.53 
115 
2.31 
15 
2.10 
Table 7.27(a) : Treated erythrocytes and SPA: Donor AJS 
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TIME VARIABLE DATE 4.7.89. 
(mins) Whole Blood PRP+Crbc PRP+Trbc PRP+Trbc 
30 Plt. no. 
RBC no. 
165 
4.45 
159 
2.24 
147 
2.30 
146 
2.19 
60 Plt. no. 
RBC no. 
144 
4.43 
169 
2.35 
154 
2.37 
156 
2.32 
90 Plt. no. 
RBC no. 
155 
4.40 
171 
2.29 
154 
2.39 
150 
2.33 
See also figure 7.14. 
The degree of SPA at t=90 minutes in each sample was as follows; 
%SPA, Whole blood (21.6.89) = 8.9% 
PRP+Crbc (21.6.89) = 4.9% 
PRP+Nrbc (21.6.89) = 94.2% 
Whole blood (4.7.89) = 12.7% 
PRP+Crbc (4.7.89) =0 
PRP+Trbc(i) (4.7.89) =0 
PRP+Trbc(ü)(4.7.89) = 3.8% 
Untreated whole blood shows only a small degree of SPA under the conditions of this 
experiment. Similarly, the reconstituted samples comprising PRP and "control" erythrocytes 
or "trypsinised" erythrocytes show only minimal SPA. 
178 
8 0 
A 
0 
0 
K 
N 
O 
O 
r 
A. 
200 
'Whole Blood' S. P. A. 
1 Donor A. J. S. (21.6.89) 
160 
'ý-----K yº, aýý ßýocd 
120 o-1--0-_-_ o PRP+Cr6c- 
. 80 
40 
t PRP + Nr6ý t----- 
30 66 90 
200 
160 
120 
'J 
: 44() 
FIGURE 7.14: "Whole Blood" SPA; donor AJS 
v (, 0 90 
Time from venupuncture (minutes) 
179 
In contrast, the "neuraminidase" erythrocytes cause almost total SPA within 30 
minutes of mixing commencing. If the interaction between platelets and erythrocytes was 
merely a consequence of the removal of negatively-charged sialate from the erythrocytes 
preventing the normal charge-repulsion between platelets and erythrocytes, then the 
"trypsinised" erythrocytes might be expected to cause a similar result. In these cells, the 
entire surface glycoprotein has been removed, including the terminal sialate. 
These results suggest a direct interaction between normal, healthy platelets and 
desialated erythrocyte glycoproteins and/or glycolipids, rather than a charge-dependent 
interaction. 
1,2, Is the SPA seen in reconstituted samples ADP-dependent? 
Citrated blood was collected from donor BEPS. Whole blood and reconstituted 
samples using each of the three types of fixed red cells were stirred at 3700 in the presence 
or absence of the PK/PEP ADP-destroying system. After 120 minutes, 5µM ADP was added 
to the samples containing PK/PEP to test the effectiveness of the system. 
TIME VARIABLE DATE 22.5.89 (ADP-destroying system absent) 
(mies. ) Whole Blood PRP+Crbc PRP+Trbc PRP+Nrbc 
20-25 Plt. no. 164 202 218 169 
RBC no. 4.20 1.92 1.57 1.55 
45 Plt. no. 119 110 182 31 
RBC no. 4.34 1.95 1.58 1.56 
80-90 Plt. no. 131 156 84 81 
RBC no. 4.25 1.90 1.53 1.54 
120 Plt. no. 118 278 141 130 
RBC no. 4.28 1.92 1.58 1.51 
Table 7.28(a) : Treated gn ytes and SPA: Donor BEPS. PKA'EP absent. 
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TIME VARIABLE DATE 23.5.89(ADP-destroying system present) 
(mies. ) Whole Blood PRP+Crbc PRP+Nrbc PRP+Nrbc 
20-25 Plt. no. 215 195 175 187 
RBC no. 4.31 2.14 2.00 2.03 
45 Plt. no. 210 163 81 35 
RBC no. 4.33 2.16 1.95 2.01 
65 Plt. no. 192 180 44 45 
RBC no. 4.35 2.14 1.99 2.01 
80-90 Plt. no. 183 257 120 125 
RBC no. 4.31 2.14 1.97 1.99 
120 Plt. no. 189 270 176 205 
RBC no. 4.31 2.17 1.95 1.98 
5µM ADP added to each sample 
130 Plt. no. 161 281 168 205 
RBC no. 4.09 2.12 1.91 1.92 
See also figure 7.15. 
The maximum degree of SPA in each sample was as follows; 
Whole blood = 28.0% 
PRP+Crbc = 45.5% 
PRP+Trbc = 61.7% 
PRP+Nrbc = 81.7% 
Whole blood + PK/PEP = 14.9% 
PRP+Crbc + PK/PEP = 16.4% 
PRP+Nrbc + PK/PEP(i) = 74.9% 
PRP+Nrbc + PK/PEP(ii) = 81.3% 
78.1% = mean SPA, PRP+Nrbc + PK/PEP 
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The ADP-destroying system causes an inhibition of SPA in whole blood and also in 
the reconstituted sample with "control" erythrocytes. The "trypsin" red cell experiment was 
not repeated owing to a shortage of these paticular cells on the day of the experiment. No 
inhibition of SPA was observed in the neuraminidase-treated samples. 
Compared to the previous, younger control, donor BEPS shows an enhanced SPA in 
whole blood and also a significant response to the "control" and "trypsin" erythrocytes absent 
in the younger donor. 
Owing to the differences between SPA in the presence or absence of PK/PEP, it is 
possible to divide the SPA into ADP-dependent and ADP-independent aggregation; 
Whole blood : Total SPA = 28% 
ADP-independent = 14.9% 
ADP-dependent = 13.1 % 
PRP+Crbc : Total SPA = 45.5% 
ADP-independent = 16.4% 
ADP-dependent = 29.1 % 
PRP+Nrbc : Total SPA = 81.7% 
ADP-independent = 78.1 +/- 3.2% 
ADP-dependent = 3.6 +/- 3.2% 
Like the whole blood samples, it appears that SPA in the "control" erythrocyte 
experiments can be divided into two discrete types, ADP-dependent and independent. In 
contrast, the neuraminidase-treated erythrocytes are able to cause almost total disappearance 
of platelets even in the absence of ADP. 
All the treated erythrocyte samples show a large degree of disaggregation after 
maximal SPA has occured. This long-term reversible SPA is paticularly evident in the 
"control" red cell samples where it proceeds to such an extent that the final platelet count is 
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higher than the initial, pre-mixing count. Since the phenomenon is not seen in whole blood, 
the "extra" platelets are unlikely to be due to microaggregates present in the blood at 
venupuncture. A more likely explanation is that some SPA had occured in the "control" 
erythrocyte sample between sample preparation and the first (t=30) count. 
23,7,3, Do high concentrations of sugars inhibit the interaction between platelets and 
neuraminidase-treated red cells? 
Citrated blood was collected from donor BEPS. The spontaneous aggregation of 
platelets in PRP, whole blood and in reconstituted samples using neuraminidase-treated 
erythrocytes in the presence or absence of 35mM glucose, 1 0mM galactose or 10mM N- 
acetyl-glucosamine was investigated by stirring samples at 37°C. 
TIME VARIABLE DATE 9.6.89 
(mies. ) Whole Blood PRP+Nrbc PRP+Nrbc+Glucose 
20-30 Plt. no. 208 194 211 
RBC no. 4.25 0.45 0.47 
60 Plt. no. 172 27 81 
RBC no. 4.36 0.40 0.37 
85-90 Plt. no. 144 18 13 
RBC no. 4.43 0.38 0.39 
110-120 Plt. no. 130 23 19 
RBC no. 4.44 0.35 0.35 
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TIME VARIABLE DATE 22.6.89. 
(mins. ) PRP+Crbc PRP+Nrbc PRP+Nrbc PRP+Nrbc 
+Galactose +N-A-G 
20-30 Plt. no. 235 282 287 288 
RBC no. 2.36 1.95 1.93 1.91 
60 Plt. no. 152 12 10 13 
RBC no. 2.39 1.95 1.92 1.91 
85-90 Plt. no. 110 15 15 17 
RBC no. 2.30 1.95 1.87 1.93 
110-120 Plt. no. 125 25 35 15 
RBC no. 2.41 1.96 1.90 1.91 
Table 7.29(b) : Treated erythrocytes and SPA: Donor BEPS. the effects of galactose 
The equivalent PRP sample showed no SPA, platelet number increasing from 342 to 
370x 109/1 plasma during the assay. 
See also figure 7.16. 
The maximum degree of SPA in each sample was as follows; 
Whole blood = 37.5% 
PRP+Nrbc(9.6.89) = 90.7% 
PRP+Nrbc + 35mM Glucose = 93.8% 
PRP+Crbc = 52.8% 
PRP+Nrbc(22.6.89) = 95.7% 
PRP+Nrbc + 10mM Galactose = 96.5% 
PRP+Nrbc + 10mM N-acetyl-Glucosamine = 95.5% 
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The high sugar concentrations were added in an attempt to inhibit the "interaction" 
between platelets and "sticky", desialated erythrocytes by occupying a putative receptor site 
on platelets for the new sugar residues exposed on the desialated glycoproteins of the red cell. 
Clearly, the three sugars tested have no effect on the potential of neuraminidase-treated red 
cells to induce SPA. 
Interestingly, all samples show more SPA than the equivalent samples from the same 
donor two weeks previously (section 7.3.7.2. ). Since this phenomenon is seen in whole blood 
as well as the reconstituted samples, it is unlikely to be due to a deterioration of the fixed 
erythrocytes, but to an increase in the "sensitivity" of the platelets from this donor in the 
period between experiments. 
7-3-7A-SPA in reconstituted samples with diabetic PRP. 
Citrated blood was obtained from two diabetic patients. PRP, whole blood and 
reconstituted samples using each of the three types of fixed red cell were rolled at 22°C. 
Diabetic J4: Male, age 72, IDDM, retinopathy. 
Diabetic J6: Male, age 46, IDDM, retinopathy. 
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TIME VARIABLE Whole Blood PRP+Crbc PRP+Nrbc PRP 
(minn. ) 
30 Plt. no. 180 187 236 353 
RBC no. 5.00 2.20 1.69 0 
55-60 Plt. no. 154 98 35 352 
RBC no. 5.13 2.13 1.81 0 
90-100 Plt. no. 135 64 75 334 
RBC no. 5.04 2.24 1.68 0 
120 Plt. no. 114 65 80 321 
RBC no. 4.81 2.05 1.53 0 
Table 7.30. " Treated erythrocytes and SPA: Donor. diabetic J4. 
TIME VARIABLE Whole Blood PRP+Crbc PRP+Trbc PRP+Nrbc 
(mins. ) 
30 Plt. no. 168 123 87 92 
RBC no. 3.87 2.32 2.33 1.64 
55-60 Plt. no. 137 75 48 19 
RBC no. 3.80 2.26 2.33 1.52 
90-100 Plt. no. 128 47 19 33 
RBC no. 3.77 2.24 2.30 1.40 
120 Plt. no. 125 40 19 33 
RBC no. 3.79 2.25 2.31 1.43 
See also figure 7.17. 
The maximum degree of SPA in each sample was as follows; 
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Whole blood = 36.7% 
PRP+Crbc = 65.8% 
PRP+Nrbc = 85.2% 
PRP = 9.1% 
in 
The platelet volume profiles from the Technicon H* I clearly showed that some 
platelet aggregation had occured. prior to the start of mixing at t=30, in the reconstituted 
samples. Hence, the whole blood platelet count at t=30 was used to calculate total SPA. 
Whole blood = 25.6% 
PRP+Crbc = 76.2% 
PRP+Trbc = 88.7% 
PRP+Nrbc = 88.7% 
Both diabetic patients show a considerable degree of SPA in whole blood. The 
amount of SPA, however is not significantly different from that seen in controls of a similar 
age. The results with patient J4 confirm the observation that a greater proportion of platelets 
spontaneously aggregate in whole blood than in PRP. Interestingly, both diabetics show 
marked SPA in the presence of the "control" erythrocytes. 
The reconstituted samples show very similar initial platelet counts to that seen in the 
equivalent whole blood sample. However, erythrocyte numbers are usually only around 50% 
of the number seen in whole blood. This suggests that the red cell pellet obtained by low 
speed centrifugation of the 4% cell suspensions does not contain truly "packed" cells. This 
may be due to a decrease in the deformability of gluteraldehyde-fixed red cells compared to 
fresh erythrocytes. The relatively low red cell numbers do not seem to hinder SPA. This is 
paticularly evident from experiment 7.3.7.3. On the first day of testing, the neuraminidase- 
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treated samples contained only 10% of the whole blood erythrocyte numbers owing to a 
shortage of these paticular cells. In contrast, the second day of testing provided samples with 
almost 50% of the whole blood erythrocyte number. Despite this discrepancy, the response of 
platelets on each occassion was almost identical. 
There appears to be considerable difference between individuals in their response to 
the various types of treated red cells. However, the one consistent observation is that the 
neuraminidase-treated erythrocytes cause almost total aggregation of platelets in all donors 
examined. This aggregation occurs relatively quickly, and is not dependent on ADP released 
sub-lytically from erythrocytes or secreted from platelet granules (see section 7.3.7.2. ). 
Treatment of cells with neuraminidase cleaves the terminal sialic acid residue from 
glycoproteins and glycolipids. Human erythrocytes possess four distinct membrane 
sialoglycoproteins designated a, ß, x and 8141-144. It has been suggested that several of 
these proteins associate with membrane skeletal proteins and appear to be important for the 
maintainance of the biconcave shape of the normal erythrocyte 
142,143 Loss of sialic acid by 
a neuraminidase-like activity and of glycoproteins by a proteolytic activity has been reported 
during red cell aging or nutrient depletion in vivo 141. Sialic acid depletion has been proposed 
as one method by which old red cells are recognised and removed from the circulation by the 
spleen, liver and bone mairowl35. Similarly, removal of as little as 8-10% of platelet sialic 
acid results in their recognition as "foreign" in vivo 145. 
The results described here indicate that desialated erythrocytes cause massive SPA of 
apparently normal platelets. This phenomenon is not dependent on ADP, which suggests a 
more direct form of platelet activation by the treated erythrocytes. This activation could take 
the form of platelets binding to "sticky" desialated red cells or may be due to the "activation" 
of a plasma factor by the treated red cells, which then initiates platelet aggregation. 
If desialated erythrocytes are able to cause platelet loss in vivo, then people with an 
increased turnover of red cells might be expected to be prone to increased in vivo platelet 
activation. Erythrocyte lifespan and deformability are generally recognised to be reduced in 
diabetes3,135 and thus desialation may play a major role in the development of platelet- 
erythrocyte interactions in diabetes. 
Chapter 8 
GENERAL CONCLUSIONS 
191 
Microangiopathy, the disease of small blood vessels, is rare in the general population, 
but seriously affects many sufferers of diabetes mellitus, leading to blindness, kidney failure 
and disorders of the nervous system (see section 1.8). Inappropriate in vivo platelet activation 
with microaggregate formation and subsequent capillary occlusion has been postulated to 
play a major role in the development of these complications 37,44-53 
Evidence for in vivo platelet activation is given by the presence of platelet activation 
and secretion markers in the plasma. (3-thromboglobulin48,49, thromboxane B250 and 
MDA51 have all been reported to be raised in diabetic plasma. The results reported in chapter 
3 show that, in general, the capacity of diabetic platelets to produce MDA, and hence TxA2, 
is no different from age-matched controls. This would appear to indicate that elevated plasma 
(as opposed to serum) TxB2 levels in diabetics45,50 are not due to an intrinsic fault in the 
diabetic platelets, but rather to an "over-activation" (or "under-suppression") of TxA2 
synthesis by external agonists. 
Two of the 63 diabetics tested showed significantly raised serum MDA levels 
compared to the other diabetics and controls. These observations may point to a transient 
malfunction in platelet metabolism, possibly induced by a period of poor diabetic control. 
Potentially, the platelets from these donors could cause excessive in vivo thrombosis. A 
stimulus that normally would cause only limited platelet activation might be expected to 
trigger more widespread aggregation in the presence of these "super-TxA2 producing" 
platelets. 
Further evidence for similarities in diabetic and control platelets comes from the 
responses of platelets to ADP (tables 4.3 and 6.4) and the Cat+-antagonist, verapamil (table 
4.3). There is no real difference in response to either agent, suggesting similar resting Ca2+ 
levels in platelets from both diabetics and controls. However, calcium-channel blockers may 
have a role to play in the treatment or prevention of diabetic microangiopathy. The tendency 
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for platelets to aggregate in response to a given stimulus would be diminished, and in 
addition, the chances of capillary occlusion would be reduced by the calcium-channel 
blocker's vasodilatory action. 
The fact that platelet aggregation tends to increase with age has long been 
recognised3'4. The results shown in figure 3.3 indicate that the capcity of platelets, from both 
diabetics and controls, to produce MDA does not increase significantly with donor age. Thus, 
the observed increase in sensitivity to agonists of platelets from older controls and diabetics 
may be due to an, as yet, unidentified plasma platelet aggregation-enhancing factor (chapter 
5) rather than age-dependent changes in the platelets themselves. 
The resonse of diabetic platelets to PGE1 is significantly reduced compared to non- 
diabetic platelets (table 6.4). PGE1 and its physiological equivalent, prostacyclin, share a 
common receptor on platelets4. Hence, if this situation is repeated in vivo, the anti- 
thrombotic capability of vascular endothelium will be reduced. To make matters worse, there 
have been frequent reports that diabetics synthesize less PGI2 than controls (review; ref. 45). 
A possible reason for this is the inhibition of PGI2 production by high levels of glucose43. 
The results reported in chapter 6 show that the decreased anti-aggregatory potential of PGE 1 
towards diabetic platelets is made worse by the presence of high levels of insulin. Thus, the 
actual act of infusing insulin may promote localised platelet activation in diabetics. Platelet 
microaggregates formed in this way would pass through the circulation until they were either 
dissociated, or caused occlusion of a minor blood vessel. 
Instances of poor diabetic control, with accompanying hyperglycaemia may provide a 
mechanism for transient platelet activation. Diabetic platelets need only be exposed to pro- 
aggregatory conditions for a short period of time for serious microvascular consequences to 
occur, and non-enzymatic glycosylation provides several mechanisms by which 
thrombogenesis can be accelerated (see section 1.9). 
The importance of interactions between platelets and other blood cells should not be 
underestimated. Two distinct types of interactions between platelets and red cells are 
described in chapter 7. ADP-dependent spontaneous platelet aggregation can be inhibited by 
ADP-destroying enzymes and is presumably due to ADP, released either from platelet 
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granules or, sub-lytically, from erythrocytes 125,126. The trigger for ADP-release is probably 
mechanical. Cell-cell collisions induced by blood sample stirring or rolling in vitro are the 
equivalent of cellular interactions in flowing blood. Deformations of red cells, passing 
through capillaries in vivo might be expected to cause similar effects. 
ADP-dependent spontaneous platelet aggregation appears to be at least partially due 
to direct interactions between platelets and red cells. Desialated red cells cause a massive, 
rapid decrease in platelet number. Old red cells become desialated in the circulation prior to 
removal by the liver and spleen, and these cells could be "sticky" towards platelets, 
paticularly pre-activated or "poised" platelets such as may occur during diabetic 
hyperglycaemia. Red-cell platelet aggregates are potentially even more damaging to the 
microvasculature than platelet microaggregates. 
The various mechanisms potentially involved in the development of capillary 
occlusion are summarised in figure 8.1. 
8.2.: Future Research 
A series of long-term studies, involving a relatively small number of newly diagnosed 
diabetics and regular blood samplings with tests for such variables as platelet response to 
PGEI and ADP, plasma MDA and f3-TG levels, and haemoglobin glycosylation could be 
carried out. This may establish whether there are gradual, progressive changes in platelet 
function, or sudden, transient effects that might be missed by single or infrequent samplings 
during the development of diabetic microangiopathy. 
In addition, clinical studies involving the incidence of vascular complications in two 
groups of diabetic patients, one taking a suitable Cat+-antagonist such as verapamil and the 
other taking a placebo, could be undertaken to see if the drug prevents or retards the 
development of diabetic complications. 
A new avenue of research involves flow-cytometry of platelets. Using fluorescent- 
labelled antibodies to platelet proteins, pre-activated or abnormal platelets could be detected 
in whole blood. Potential markers for platelet activation should be proteins that are only 
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expressed or bound at the platelet surface following activation. Such a technique has been 
used to identify abnormal platelets lacking the fibrinogen receptor in the bleeding disorder 
Glanzmann's Thrombosthania151. Conversely, the presence of the fibrinogen receptor on 
"resting" platelets would indicate that inappropriate platelet activation had taken place. 
Shattil et a1149 have used a monoclonal antibody, PAC-1, to the GPIIb/IIIa complex to 
characterise the expression of the complex on the surface of activated platelets. Potentially 
more useful in the search for pre-activated platelets may be antibodies to fibrinogen or other 
adhesive proteins such as von Willebrand's factor and fibronectin. Pre-activated platelets 
formed in vivo should already have fibrinogen bound, and this could interfere with the 
binding of anti-GPIIb/IIIa to the receptor 148. McEver and Martin 150 have developed an 
antibody, S12, to a protein, normally found in the platelet alpha-granules, that becomes 
surface-expressed following thrombin activation of platelets. This protein presumably 
appears at the platelet plasma membrane following the release reaction and fusion of granules 
with the external membrane. Its presence on the surface of "resting" platelets would be 
indicative of serious in vivo platelet activation. 
Flow-cytometry techniques can be performed with very small volumes of blood and 
could give an indication as to whether all platelets become equally "activated" in the pre- 
thrombotic state, or only an abnormal population of "hypersensitive" platelets. 
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ARoendix 1: Platelet AQgEUometrv 
(a) Preparation of PRP and PPP 
Whole blood is collected by venepuncture, either into a special "Vacutainer", or, via a 
syringe, into a 12.5m1 plastic centrifuge tube containing an appropriate anticoagulant. 
All glass and plastic-ware is siliconised using "Sigmacote" (Sigma) prior to use to 
prevent interactions between platelets and their container. 
PRP is prepared by centifuging whole blood at approximately 100g for 10-20 minutes 
at room temperature. Older controls and diabetics require a shorter centrifugation period than 
young controls. Typically, 10ml of whole blood yields 3-5m1 of PRP. PRP is carefully 
removed from above the sedimented red and white cells using a plastic disposable pipette, 
and transferred to a second container. 
PPP is prepared by centrifuging the remaining red and white cells at 1000g for 10 
minutes. 
The platelet aggregometer is a specially adapted spectrophotometer, fitted with a 
magnetic stirrer base, chart recorder, and usually a 37°C thermo-stat. Aggregometry works 
on the principle that a large number of small particles (platelets) scatters more light than a 
small number of large particles (platelet aggregates). Hence, as platelets aggregate there is a 
gradual decrease in optical density. 
1. Oml PRP samples are transferred to 3.0ml aggregometry cuvettes (LIP Ltd. ). The 
aggregometer "zero" is set using PPP as a blank, and adjusting the OD (600nm) to 0.1 on the 
chart recorder scale. A PRP sample is used to set the starting OD to 0.9 on the chart scale. 
Mixing is commenced by adding a small, siliconised magnetic stirrer bar to the 
cuvette and switching on the stirrer at a speed of 500-1200rpm. 
After following the progress of any spontaneous aggregation for a few minutes, a 
small volume ("'l0µ1) of a platelet agonist is added. 
Initially, there is a small increase in OD, corresponding to the platelet shape change, 
followed by a rapid decrease in OD due to platelet aggregation. 
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Three types of platelet aggregation may be obtained with ADP; reversible aggregation 
occurs at low agonist concentration and coincides with primary platelet aggregation without 
large scale granule release and "tight" aggregate formation. These 10 agregates 
spontaneously dissociate to give individual platelets. The shape change, however, is 
irreversible. Irreversible aggregtion is seen at higher agonist concentrations, sufficient to 
cause rapid and complete granule release and 20 aggregation. Biphasic aggregation occurs at 
a concentration of agonist that is only just capable of causing granule release, hence the two 
phases of aggregation are visually separate. (See figure Al) 
Appendix 2: Platelet Density Centrifugation 
(Personal communication, G. M. Wilkins) 
PRP is obtained as described in appendix 1, and a 2. Om1 sample layered onto a 
column of "Percoll" of density 1.04g/ml to 1.09g/ml. 
The column is created as a discontinuous gradient with 2m1 steps of "Percoll" of 
densities; 1.09,1.08,1.07,1.065,1.06,1.05 and 1.04g/ml. Each gradient step is prepared 
containing 150nm PGE1 to prevent platelet activation during centrifugation. 
Gradients are centrifuged at 30,000g for 30 minutes in a swing-out rotor, resulting in 
the formation of a pseudo-linear density gradient, and up to 15 discrete bands of platelets in 
the density range 1.055-1.068 g/ml. (see figure A2). 
On aggregation, platelets secrete their granule contents and decrease in density. 
Hence, any platelet aggregates present are visible at a higher position on the gradient. 
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